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Summary 
Background: Gastrointestinal infections are among the leading causes of morbidity worldwide. In 
contrast to acute diarrhoea, long-lasting digestive disorders can be defined as persistent diarrhoea (≥14 
days) and/or persistent abdominal pain (≥14 days). This clinical syndrome is frequently caused by 
intestinal infections, but its medical importance in the tropics, the range of causative pathogens and the 
contribution of neglected tropical diseases remain to be elucidated. Currently employed diagnostic 
tools for the detection of intestinal pathogens frequently lack sensitivity, and there are only few 
evidence-based recommendations to guide the clinical management of persistent digestive disorders in 
resource-constrained settings. Rapid diagnostic tests (RDTs) have become available for the diagnosis 
of various intestinal pathogens and hold promise to be used even in peripheral healthcare centres with 
only very limited laboratory infrastructure. More recently, multiplex polymerase chain reaction (PCR) 
assays targeting gastrointestinal pathogens have been developed, but these tests have yet to be 
systematically evaluated in the tropics. The current Ph.D. thesis was carried out as part of the NIDIAG 
project, an international research consortium that aims at developing evidence-based diagnosis-
treatment algorithms for persistent digestive disorders and other common clinical syndromes in 
resource-constrained settings of Africa and Asia. 
 
Methods: A systematic review was performed to elucidate the aetiological spectrum of persistent 
digestive disorders. A study protocol, accompanied by a set of more than 30 standard operating 
procedures (SOPs), was developed to conduct a multi-country, prospective case-control study to 
investigate persistent diarrhoea (≥14 days; all individuals aged above 1 year) and persistent abdominal 
pain (≥14 days; all children and adolescents aged 1-18 years) in Côte d’Ivoire, Indonesia, Mali and 
Nepal. In the framework of a specific site assessment, a case-control study was performed in Dabou, 
south Côte d’Ivoire to determine the aetiology and clinical features of persistent diarrhoea. Stool 
samples were subjected to a host of microscopic techniques, RDTs for Clostridium difficile, 
Cryptosporidium spp. and Giardia intestinalis, as well as the Luminex
®
 Gastrointestinal Pathogen 
Panel, a stool-based multiplex PCR. A subsequent study was conducted to assess the diagnostic 
accuracy of real-time PCR for detection of Strongyloides stercoralis and to compare it to a 
combination of microscopic methods (Baermann funnel concentration and Koga agar plate). For the 
first time, a previously validated, urine-based RDT for the diagnosis of Schistosoma mansoni was 
employed for individual management of patients presenting with digestive disorders to a hospital in 
Europe.   
 
Results: The systematic review identified more than 40 bacterial, parasitic (helminths and intestinal 
protozoa) and viral pathogens that may potentially cause persistent diarrhoea and persistent abdominal 
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pain. In a subsequent case-control study in southern Côte d’Ivoire, 20 different intestinal pathogens 
were detected and >50% of all participants had co-infections. Enterotoxigenic Escherichia coli (32%) 
and Shigella spp. (20%) were the most prevalent bacterial pathogens, while G. intestinalis (29%) and 
S. stercoralis (10%) were the predominant intestinal protozoon and helminth species, respectively. 
With regard to infection status, there were few differences between cases and controls. Most patients 
with persistent diarrhoea lived in rural areas, but clinical signs and symptoms could not distinguish 
between specific infections. The protocol for the multi-country NIDIAG study on persistent digestive 
disorders adopted a case-control approach and regular follow-up visits of symptomatic patients to 
monitor the clinical response to treatment. 
A diagnostic study in south-central Côte d’Ivoire found that the application of a stool-based real-
time PCR for S. stercoralis substantially improved the detection rate of this pathogen, leading to a 
total prevalence of 21.9%, compared to a prevalence of 10.9% according to stool microscopy. 
C. difficile could also be detected in stool samples from Côte d’Ivoire (5.4% prevalence according to 
RDT). Non-toxigenic C. difficile strains predominated and their molecular characteristics differed 
considerably from those observed in other settings. Prolonged storage without properly maintained 
cold chain only minimally affected the subsequent recovery of C. difficile and its toxins in stool 
culture. 
A point-of-care (POC) test detecting a circulating cathodic antigen (CCA) in urine was 
successfully utilised to confirm intestinal S. mansoni infection in migrants from Eritrea who presented 
to a European hospital because of persistent abdominal pain. 
 
Conclusions: Persistent digestive disorders are of considerable public health importance in Côte 
d’Ivoire and elsewhere, with the majority of cases being detected in rural areas. Many different 
causative agents may give rise to this syndrome and they can be accurately detected by the application 
of highly sensitive diagnostic techniques. The diversity of the potentially implicated pathogens 
underscores the need for a syndromic approach to persistent digestive disorders. RDTs are helpful 
tools for the detection of specific pathogens and may be implemented as part of diagnostic algorithms 
in endemic areas and in hospitals providing care for migrants and returning travellers. There is an 
urgent need to develop a stool-based RDT for S. stercoralis. The high asymptomatic carriage rates of 
intestinal pathogens call for the inclusion of healthy controls in epidemiological studies to define the 
specific contribution of each pathogen to the syndrome of persistent digestive disorders. Future studies 
employing metagenomic approaches will provide further insights into the intestinal microbiome of 
symptomatic patients and healthy controls.  
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Zusammenfassung 
Hintergrund: Gastrointestinale Infektionen gehören zu den wichtigsten Infektionskrankheiten 
weltweit. Im Gegensatz zur akuten Diarrhoe können länger anhaltende Erkrankungen des 
Gastrointestinaltrakts als persistierende Diarrhoe (≥14 Tage Dauer) und/oder persistierende 
abdominelle Schmerzen (≥14 Tage Dauer) definiert werden. Dieses klinische Syndrom wird häufig 
durch Infektionserreger bedingt, aber die medizinische Bedeutung desselben in den Tropen sowie das 
Spektrum an verursachenden Pathogenen sind unvollständig verstanden. Die am häufigsten 
eingesetzten diagnostischen Verfahren zum Nachweis intestinaler Pathogene sind wenig sensitiv und 
es gibt nur wenige Evidenz-basierte Empfehlungen zum klinischen Management von persistierenden 
Erkrankungen des Intestinaltrakts. Neue Antigen-Schnelltests wurden entwickelt, die auch außerhalb 
von diagnostischen Laboratorien eingesetzt werden können. Darüber hinaus stehen auch neue 
molekulardiagnostische Verfahren (z.B. Multiplex Polymerase-Ketten-Reaktion (PCR)) zum sehr 
sensitiven Nachweis von Durchfallerregern zur Verfügung, aber diese Testverfahren sind bisher kaum 
in den Tropen eingesetzt und evaluiert worden. Dieses Dissertationsprojekt ist Teil des NIDIAG-
Forschungskonsortiums, einem Zusammenschluss verschiedener Forschungsinstitutionen, welche das 
Ziel verfolgen, Evidenz-basierte Algorithmen für eine bessere Diagnostik und Therapie von 
persistierenden Durchfallerkrankungen und persistierenden abdominellen Schmerzen in 
ressourcenschwachen Regionen der Tropen zu entwickeln. 
Methoden: Eine systematische Literaturrecherche wurde durchgeführt, um eine Übersicht über das 
Spektrum an infektiösen Erregern, welche persistierende Erkrankungen des Intestinaltrakts 
verursachen können, sowie die geeigneten diagnostischen Methoden zum Nachweis dieser Pathogene 
zu erarbeiten. Es wurde ein detailliertes Studienprotokoll für eine multizentrische, prospektive Fall-
Kontroll-Studie zur Erforschung der persistierenden Diarrhoe und persistierender abdomineller 
Schmerzen in der Elfenbeinküste, Indonesien, Mali und Nepal erstellt. Im Rahmen einer ersten 
Untersuchung wurde das Auftreten von persistierender Diarrhoe in der Stadt Dabou im Süden der 
Elfenbeinküste untersucht. Menschliche Stuhlproben wurden dabei mit einer Vielzahl von 
konventionellen und molekularbiologischen diagnostischen Tests untersucht. Außerdem wurden 
Antigen-Schnelltests zum Nachweis von Clostridium difficile, Cryptosporidium spp. und 
Giardia intestinalis durchgeführt. In einer weiteren Studie wurden unterschiedliche Labormethoden 
hinsichtlich ihrer Sensitivität und diagnostischen Aussagekraft bei Infektionen mit dem Nematoden 
Strongyloides stercoralis verglichen. Schließlich wurde ein weiterer Antigen-Schnelltest, welcher den 
Saugwurm Schistosoma mansoni detektiert, zur Versorgung eritreischer Patienten mit persistierenden 
Bauchschmerzen in einem europäischen Krankenhaus evaluiert.   
Ergebnisse: Die systematische Literaturrecherche ergab, dass mehr als 40 bakterielle, parasitäre 
(Helminthen und intestinale Protozoen) und virale Pathogene persistierende Erkrankungen des 
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Verdauungstraktes hervorrufen können. In der nachfolgenden Fall-Kontroll-Studie in Dabou wurden 
20 unterschiedliche Pathogene detektiert, wobei mehr als >50% aller Teilnehmer mehrere 
Coinfektionen aufwiesen. Die am häufigsten detektierten Pathogene waren Enterotoxin-bildende 
Escherichia coli (32%), G. intestinalis (29%), Shigella spp. (20%) und S. stercoralis (10%). Sowohl 
hinsichtlich der Prävalenzen einzelner Pathogene als auch bezüglich der Rate der detektierten 
Coinfektionen gab es kaum Unterschiede zwischen symptomatischen Patienten und asymptomatischen 
Kontrollen. Die meisten Patienten mit persistierender Diarrhoe lebten in ländlichen Gegenden und die 
klinischen Symptome waren wenig spezifisch. Basierend auf den Daten dieser Vorstudie wurden 
sowohl asymptomatische Kontrollpersonen als auch standardisierte Verlaufsbeobachtungen von 
behandelten Patienten mit persistierender Diarrhoe in das Studienprotokoll der multizentrischen 
NIDIAG-Studie aufgenommen.  
Eine weitere Diagnostikstudie in der Elfenbeinküste ergab, dass die Anwendung eines Stuhl-
basierten PCR-Verfahrens zum Nachweis von S. stercoralis deutlich sensitiver ist als die alleinige 
Durchführung mikroskopischer Verfahren (Prävalenz 21.9% vs. 10.9%). Ein Schnelltest für C. difficile 
ergab außerdem ein positives Ergebnis in 5.4% der untersuchten Proben. Weitere Analysen zeigten, 
dass die gefundenen Stämme von C. difficile keine Toxine bildeten und deutlich andere Ribotyp-
Muster als in anderen Regionen der Welt aufwiesen. Eine lange Stuhlproben-Transportzeit unter nicht 
standardisierten Bedingungen hatte keinen Einfluss auf die Sensitivität später durchgeführter 
bakteriologischer Stuhlkulturen zum Nachweis von C. difficile. 
Schließlich wurde auch ein Urin-basierter Schnelltest, welcher ein zirkulierendes kathodisches 
Antigen von Schistosoma mansoni nachweist, erstmals in Europa bei Patienten aus Eritrea erfolgreich 
zum Nachweis einer intestinalen Schistosomiasis eingesetzt. 
Schlussfolgerungen: Persistierende Durchfallerkrankungen und persistierende Bauchschmerzen sind 
relevante klinische Probleme in der Elfenbeinküste und anderswo in tropischen Regionen. Eine 
Vielzahl von Pathogenen kann diese Erkrankungen, welche besonders Menschen in armen, ländlichen 
Gebieten betreffen, hervorrufen. Der Einsatz hochsensitiver molekularbiologischer 
Diagnostikverfahren kann sehr viele dieser Krankheitserreger nachweisen. Antigen-Schnelltests 
können auch außerhalb von gut ausgerüsteten diagnostischen Laboratorien eingesetzt werden und 
sollten daher nach Möglichkeit bei der Entwicklung von klinisch-diagnostischen Algorithmen zum 
Management dieses Syndroms mit einbezogen werden. Der baldigen Entwicklung eines Schnelltest-
Nachweisverfahrens für S. stercoralis sollte eine hohe Priorität zukommen. Aufgrund des sehr 
häufigen Nachweises von Pathogenen auch bei gesunden Individuen sollten epidemiologische Studien 
auch asymptomatische Kontrollpersonen untersuchen. Der akkuraten Beschreibung des intestinalen 
Mikrobioms wird in der Zukunft eine große Rolle zum besseren Verständnis von intestinalen 
Infektionen zukommen. 
Résumé 
 
__________ 
V 
Résumé 
Contexte: Les infections gastro-intestinales sont parmi les principales causes de morbidité 
dans le monde entier. Contrairement à la diarrhée aiguë, les troubles digestifs persistants sont 
définis comme une diarrhée persistante (≥14 jours) et/ou une douleur abdominale persistante 
(≥14 jours). Ce syndrome clinique est souvent causé par des infections intestinales, mais son 
importance médicale dans les régions tropicales, la gamme d'agents pathogènes étiologiques 
et la contribution des maladies tropicales négligées ne sont pas encore bien compris. Les 
techniques diagnostiques les plus souvent utilisées pour la détection de pathogènes intestinaux 
manquent souvent de sensibilité, et il n’y a actuellement que peu de recommandations 
factuelles pour guider la gestion clinique des troubles digestifs persistants dans les milieux 
aux ressources limitées. Des Tests de Diagnostic Rapides (TDR) ont été développés pour le 
diagnostic de certains agents pathogènes intestinaux et ils peuvent également être utilisés dans 
les centres de santé périphériques sans accès à l'infrastructure d’un laboratoire. Plus 
récemment, des tests utilisant la réaction en chaîne par polymérase (PCR) pour la détection 
des agents pathogènes gastro-intestinaux ont été développés, mais ces tests doivent encore 
être évalués systématiquement dans les zones tropicales. Cette thèse de doctorat a été réalisée 
dans le cadre du projet NIDIAG, un consortium de chercheurs internationaux qui vise à 
développer des algorithmes fondées sur des preuves de diagnostic et de traitement pour les 
troubles digestifs persistants et d'autres syndromes cliniques communs dans les milieux aux 
ressources limitées de l’Afrique et de l’Asie. 
 
Méthodes: Une recherche systématique a été effectuée pour élucider le spectre étiologique 
des troubles digestifs persistants. Un protocole d'étude, accompagné d’une trentaine de 
Procédures Opératoires Standardisées (SOP), a été développé pour effectuer une étude 
prospective cas-témoins pour évaluer la diarrhée persistante (≥14 jours; tous les individus 
âgés de plus de 1 an) et la douleur abdominale persistante (≥14 jours; tous les enfants et 
adolescents âgés de 1-18 ans) en Côte d’Ivoire, en Indonésie, au Mali et au Népal. Dans le 
cadre de l'évaluation spécifique du site, une étude cas-témoins a été réalisée à Dabou, au sud 
de la Côte d’Ivoire afin de déterminer l’étiologie et les caractéristiques cliniques de la diarrhée 
persistante. Des échantillons de selles ont été soumis à une série de techniques 
microscopiques, TDR pour Clostridium difficile, Cryptosporidium spp. et Giardia intestinalis, 
ainsi que le «Gastrointestinal Pathogen Panel» de Luminex
®
, une PCR multiplex. Une autre 
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étude a été menée pour évaluer la précision diagnostique de la PCR en temps réel pour la 
détection de Strongyloides stercoralis et de la comparer à une combinaison de méthodes 
microscopiques (technique de Baermann et la plaque de gélose de Koga). Pour la première 
fois, un TDR utilisant l'urine pour le diagnostic de Schistosoma mansoni a été utilisée pour la 
gestion individuelle des patients présentant des troubles digestifs dans un hôpital européen. 
 
Résultats: Cette recherche systématique a permis d’identifier plus de 40 bactéries, parasites 
(helminthes et protozoaires intestinaux) et virus qui peuvent potentiellement causer une 
diarrhée persistante et une douleur abdominale persistante. Dans une étude cas-témoins au sud 
de la Côte d'Ivoire, 20 agents pathogènes intestinaux différents ont été détectés et >50% des 
participants ont présenté des co-infections. Escherichia coli entérotoxigènes (32%) et Shigella 
spp. (20%) étaient les agents pathogènes bactériens les plus prévalents, et G. intestinalis 
(29%) et  S. stercoralis (10%) étaient les espèces des protozoaires intestinaux et d’helminthes 
prédominantes, respectivement. Concernant le statut de l'infection, peu de différences ont été 
trouvées entre les cas et les témoins. La plupart des patients atteints de diarrhée persistante 
vivaient dans les zones rurales, cependant les signes et symptômes cliniques ne permettaient 
pas de faire la distinction entre les infections spécifiques. Le protocole de l’étude 
multicentrique sur les troubles digestifs persistants du projet NIDIAG a adopté une approche 
cas-témoins ainsi que des visites de suivi régulières des patients symptomatiques pour 
surveiller leur réponse clinique au traitement. 
Une étude de diagnostic dans le centre-sud de la Côte d'Ivoire a montré que 
l'application d'une PCR à temps réel pour S. stercoralis permettait de détecter ce pathogène de 
manière beaucoup plus sensible, conduisant à une prévalence totale de 21.9%, en 
comparaison à une prévalence de 10.9% avec l'examen microscopique des selles. C. difficile 
pouvait également être détecté dans les échantillons de selles provenant de Côte d'Ivoire 
(5.4% de prévalence en fonction du TDR). Les souches non-toxigènes de C. difficile 
prédominaient et leurs caractéristiques moléculaires différaient considérablement de celles 
observées dans d'autres régions. Un stockage prolongé en l’absence d’une chaîne du froid 
appropriée n’affectait que très peu la récupération ultérieure de C. difficile et de ses toxines 
dans la culture des selles. 
Un point-of-care (POC), soit un test de détection de l'antigène cathodique circulant 
(CCA) dans l'urine, a été utilisé avec succès pour confirmer l'infection intestinale à 
S. mansoni chez des migrants érythréens qui se sont présentés à un hôpital européen en raison 
de douleurs abdominales persistantes. 
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Conclusions: Les troubles digestifs persistants sont d’une importance considérable pour la 
santé publique en Côte d’Ivoire et ailleurs, avec une majorité de cas détectée en zones rurales. 
De nombreux agents pathogènes distincts peuvent donner lieu à ce syndrome et ils peuvent 
être détectés avec précision par l’application de techniques de diagnostic très sensibles. La 
diversité des agents pathogènes potentiellement impliqués souligne la nécessité d'une 
approche syndromique des troubles digestifs persistants. Les TDR sont des outils utiles pour 
la détection d'agents pathogènes spécifiques et peuvent être mis en œuvre dans le cadre 
d’algorithmes de diagnostic dans les zones endémiques et dans les hôpitaux offrant des soins 
pour les migrants et les voyageurs de retour. Il y a un besoin urgent de développer un TDR 
basé sur les échantillons de selles pour la détection de S. stercoralis. Du fait des taux élevés 
de porteurs de pathogènes intestinaux asymptomatiques, il est nécessaire d’inclure des 
témoins en bonne santé dans les études épidémiologiques pour définir la contribution 
spécifique de chaque agent pathogène au syndrome des troubles digestifs persistants. Les 
futures études utilisant des approches de métagénomique fourniront de nouvelles informations 
sur le microbiome intestinal des patients symptomatiques et des témoins asymptomatiques.
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1 Introduction 
 
1.1  Global burden of disease and the role of infectious disorders 
A comprehensive assessment of the prevalence, incidence and distribution of major diseases 
at a global scale is essential to quantify the state of health and well-being of entire 
populations and to identify major health problems. Initiated by the World Health 
Organization (WHO) and the World Bank, the Global Burden of Disease (GBD) study was 
designed to provide a standardised approach for the assessment of health worldwide [1]. In 
the 1990s, the first GBD study summarised the global state of health and provided – for the 
first time – data on the attribution of specific diseases and injuries to the global disease 
burden [2]. The introduction of the ‘disability-adjusted life year’ (DALY) metric was an 
essential development to consider not only deaths due to specific diseases, but also the 
associated disability that is linked to clinical conditions. DALY is defined as “the sum of life 
years lost due to premature mortality and years lived with disability adjusted for severity” [3]. 
The first GBD study identified that 43.9% of all DALYs worldwide could be attributed to 
communicable, maternal, perinatal and nutritional disorders, with lower respiratory 
infections, diarrhoeal diseases, tuberculosis and measles ranking among the most important 
specific causes. If considering different regions of the world, sub-Saharan Africa was found 
to suffer from the highest burden of infectious diseases. Indeed, infectious disorders 
accounted for a considerable amount of deaths and for 53% of the total DALY burden in this 
region [4].  
 
A comprehensive update on the global state of health and disease was published in late 2012, 
when results from the GBD 2010 study were presented. A series of significant changes were 
observed between 1990 and 2010. While the global burden of DALYs decreased only slightly 
by 0.5% to a total of 2,490,385,000 DALYs, the burden due to communicable diseases could 
be reduced by 26.5% [5]. Major contributors to such considerable improvement were the 
reduction of the disease burden due to diarrhoeal diseases (–51.2%), lower respiratory 
infections (–44.2%), meningitis (–22.3%) and tuberculosis (–19.4%). In 2010, ischaemic 
heart disease replaced lower respiratory infections as the leading cause of disease burden at a 
global scale, but lower respiratory infections and diarrhoeal diseases still ranked second and 
fourth on the list of the most important causes of DALYs worldwide. Despite the global trend 
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to improved health reported in the GBD study 2010, the authors acknowledged enormous 
epidemiological heterogeneity in different geographical, social and ecological settings. If the 
total global burden was stratified by geographical regions, it became apparent that Eastern 
sub-Saharan Africa was the only African area in which a slight decrease in terms of DALYs 
was observed between 1990 and 2010 (–1.3%), while the total disease burden expressed in 
DALYs increased between 19.0% and 85.0% in Western, Central and Southern sub-Saharan 
Africa. Additionally, while communicable, maternal, neonatal and nutritional disorders 
accounted for 67-71% of the total disease burden in sub-Saharan Africa, these diseases 
contributed less than 10% to the disease burden of North America and Western Europe [5]. 
 
In August 2015, an analysis of the GBD study 2013 was published to provide the most recent 
update on the global disease burden [6]. A clear overall trend towards an improved global 
health was confirmed, but the global DALY burden decreased only minimally by 3.6% 
despite major health improvements, which can mainly be explained by a rise in life 
expectancy and population growth in some parts of the world. Indeed, if stratified by age, the 
global DALYs dropped by 27% between 1990 and 2013. The authors reported an ongoing 
‘epidemiological transition’, i.e. an increase in DALYs due to non-communicable diseases 
and a further decline in many communicable diseases. Yet, the researchers acknowledged that 
the achieved decline, e.g. pertaining to lower respiratory infections, was not sufficient “for 
these conditions to be replaced as the leading causes of disease burden worldwide” [7]. 
Indeed, HIV/AIDS, malaria, respiratory infections, diarrhoeal diseases and tuberculosis 
continue to constitute the principal specific causes of disease and suffering in most countries 
of sub-Saharan Africa and in parts of Asia (Table 1.1). Of note, the GBD 2013 study reported 
also a significant increase in the burden due to a number of tropical and poverty-associated 
infections such as dengue fever, food-borne trematodiasis and leishmaniasis. 
 
When analysing the global causes of child deaths in the GBD 2013 study, communicable, 
neonatal and nutritional deficiencies accounted for three-quarters of all deaths, even though 
the total number of premature child deaths could be reduced by approximately 50% since 
1990 [6]. Diarrhoeal diseases, meningitis and lower respiratory infections were responsible 
for the majority of deaths. Eastern, central and western sub-Saharan Africa had substantially 
higher child mortality than all other regions of the world. The aetiological cause of diarrhoeal 
diseases remained unclear in at least 55.6% of all cases, which can be explained by the lack 
of epidemiological data and the insufficient sensitivity of many laboratory diagnostic tests. 
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Rotavirus played a major role in young children, but bacterial pathogens such as Shigella spp. 
and Vibrio cholerae and the intestinal protozoa Cryptosporidium spp. were also important 
pathogens. The bacterium Clostridium difficile was of considerable importance outside low-
income countries and accounted for up to 95% of all diarrhoea-associated deaths in elderly 
people in high-income countries, particularly in North America and Western Europe [6]. 
  
 
Table 1.1 The three most important causes of disease (assessed by attribution of DALYs 
to each of the conditions) in 15 selected countries in 2013 (adapted from [7]). 
 #1 cause of disease #2 cause of disease #3 cause of disease 
Australasia   
 Australia Low back and neck pain Ischaemic heart disease Depression 
North America   
 United States of  
.America 
Ischaemic heart disease Low back and neck pain Chronic obstructive 
pulmonary disease 
Western Europe   
 Germany Low back and neck pain Ischaemic heart disease Stroke 
 Italy Low back and neck pain Ischaemic heart disease Alzheimer’s disease 
 Switzerland Low back and neck pain Ischaemic heart disease Falls 
Latin America   
 Brazil Ischaemic heart disease Low back and neck pain Violence 
 Peru Lower respiratory infections Low back and neck pain Ischaemic heart disease 
Middle East   
 Syria War Ischaemic heart disease Stroke 
South and Southeast Asia   
 China Stroke Low back and neck pain Ischaemic heart disease 
 Indonesia Stroke Ischaemic heart disease Tuberculosis 
 Nepal Lower respiratory infections Ischaemic heart disease Low back and neck pain 
Sub-Saharan Africa   
 Côte d’Ivoire Lower respiratory infections HIV/AIDS Malaria 
 D.R. Congo Diarrhoeal diseases Lower respiratory infections Malaria 
 Mali Malaria Diarrhoeal diseases Lower respiratory 
infections 
 South Africa HIV/AIDS Tuberculosis Lower respiratory 
infections 
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1.2  Neglected tropical diseases 
In many resource-constrained countries in tropical and subtropical areas, health systems are 
weak and the few available resources have to be allocated to the most urgent health problems. 
In terms of infectious diseases affecting populations living in the tropics and subtropics, 
HIV/AIDS, malaria and tuberculosis constitute the ‘big three’ to which most attention and 
funding is typically addressed [8]. In September 2000, the United Nations General Assembly 
adopted the Millennium Declaration, in which eight Millennium Development Goals (MDGs) 
were specified with the overarching aim to reduce the massive burden due to poverty, 
diseases, weak health systems and hunger by 2015 [9]. As a direct result, funding and 
research on many infectious diseases, particularly the ‘big three’, increased considerably. 
However, an increasing number of researchers acknowledged that a host of infectious 
diseases continued to cause enormous morbidity in tropical and subtropical areas, but their 
health impact remained hardly ever assessed and quantified, and little funding was available 
to tackle these diseases. In several manuscripts published in 2005-2007, the term ‘neglected 
tropical diseases’ (NTDs) was used to summarise this group of infectious diseases [10,11]. 
 
The original list of NTDs comprised 13 major infectious diseases of bacterial, helminthic and 
protozoal origin [12]. Common key characteristics of these diseases are their mainly chronic 
character as well as their intimate connection to poverty and populations living in the most 
remote settings of low-income countries in the tropics and subtropics [13]. Many NTDs are 
clustered in similar geographical areas, thus leading to a substantial amount of co-infections 
with multiple pathogens in areas of endemicity [14]. Poor sanitation and hygiene, lack of 
adequate access to water and resources and a lack of health education are typical risk factors 
for acquisition of NTDs [8,15]. Children are considered to be most heavily affected by many 
NTDs and often suffer most from these debilitating diseases. While the long-term morbidity 
due to the mainly chronic NTDs is considerable, acute severe disease manifestations and 
subsequent deaths are rarely encountered. Hence, quantification of the disease burden due to 
NTDs is extremely challenging and relies on morbidity indicators such as DALYs or the 
more recently introduced qualiy-adjusted life years (QALYs) [16]. However, the lack of 
reliable epidemiological data on the occurrence of many NTDs, the poorly understood 
clinical symptomatology and the high rates of co-infections with multiple pathogens render 
pathogen- or disease-specific estimates of attributable DALYs a difficult task, e.g. in the case 
of intestinal parasitic infections [17]. Many helminths and intestinal protozoa may give rise to 
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abdominal symptoms such as pain, diarrhoea, abdominal tenderness or blood in the stool, yet 
few studies in endemic countries have generated epidemiological data on the role and 
attributable fraction of NTDs to this syndrome [18]. Additionally, some NTDs lead to 
enormous, frequently stigmatising long-term morbidity that persists for long time periods 
even after the infection is cleared. One prominent example is lymphatic filariasis, an infection 
that is mainly caused by the nematode Wuchereria bancrofti, and that is one of the leading 
causes of lymphoedema and hydrocoele in sub-Saharan Africa [19-21]. According to a recent 
analysis of the GBD 2010 study, it was estimated that the individual DALY estimates of the 
various NTDs may, if taken together, amount to 48 million DALYs, which is in the same 
range as tuberculosis (49 million DALYs in the GBD 2010) [22]. 
 
The original list of NTDs has expanded considerably over the past decade, and more recent 
reviews classify more than 40 diseases as NTDs [8]. Table 1.2 provides a comprehensive 
overview about the major diseases and the respective aetiological agents. A majority of the 
NTDs primarily causes gastrointestinal disorders and, hence, digestive symptomatologies are 
commonly seen in infected individuals. Helminths represent the largest group within the 
NTDs; while intestinal schistosomiasis [23,24], soil-transmitted helminthiasis [25], 
enterobiasis, food-borne trematodiasis [26,27] and others mainly affect the host’s 
gastrointestinal tract, an important second group is being constituted by tissue-invading 
helminths with the potential to cause severe diseases, such as Echinococcus granulosus and 
E. multilocularis, the agents of cystic and alveolar echinococcosis, respectively, and 
Taenia solium, the cause of (neuro-)cysticercosis [28,29]. Further parasitic NTDs are caused 
by intestinal protozoa, which may also be categorised into intestinal protozoa (e.g. 
Cryptosporidium spp., Entamoeba histolytica) and tissue-invasive parasites (e.g. 
Leishmania spp.) [30-32]. Cholera, salmonellosis and shigellosis are the main bacterial NTDs 
that primarily lead to abdominal or intestinal symptoms. In contrast, there are also some viral 
(e.g. dengue virus), fungal (e.g. Paracoccidioides brasiliensis) and ectoparasitic pathogens 
(e.g. Sarcoptes scabiei) listed as specific causes of NTDs [33], but they are seldom associated 
with digestive symptoms and can usually be differentiated on clinical grounds from the 
pathogens that give rise to intestinal diseases. 
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Table 1.2 A comprehensive list of helminthic, protozoal, bacterial, fungal, viral and 
ectoparasitic neglected tropical diseases (adapted from [8]). 
Neglected tropical disease Causative agent(s) 
Helminthic infections  
 Cysticercosis/taeniasis Taenia solium 
 Taenia saginata 
 Diphyllobothrium latum 
 Dracunculiasis Dracunculus medinensis 
 Echinococcosis Echinococcus granulosus 
 Echinococcus multilocularis (less common: other Echinococcus spp.) 
 Enterobiasis Enterobius vermicularis 
 Food-borne trematodiasis  
- Clonorchiasis Clonorchis sinensis 
- Fascioliasis Fasciola gigantica and F. hepatica 
- Intestinal fluke infections Echinostoma spp., Fasciolopsis buski, Metagonimus spp. and Heterophyidae 
- Opisthorchiasis Opisthorchis felineus, O. viverrini 
- Paragonimiasis Paragonimus spp. 
 Loiasis Loa loa 
 Lymphatic filariasis Wuchereria bancrofti, Brugia malayi and B. timori 
 Mansonellosis Mansonella perstans, M. streptocerca and M. ozzardi 
 Onchocerciasis Onchocerca volvulus 
 Schistosomiasis Schistosoma guineensis, S. haematobium, S. intercalatum, S. japonicum, 
S. mansoni and S. mekongi 
 Soil-transmitted helminthiasis  
- Ascariasis Ascaris lumbricoides 
- Hookworm infection Ancylostoma duodenale and Necator americanus 
- Strongyloidiasis Strongyloides stercoralis 
- Trichuriasis Trichuris trichiura 
 Toxocariasis Toxocara canis and T. cati 
 Trichinellosis Trichinella spiralis and other Trichinella spp. 
Protozoal infections  
 Balantidiasis Balantidium coli 
 Chagas disease Trypanosoma cruzi 
 Human African trypanosomiasis Trypanosoma brucei gambiense and T. b. rhodesiense 
 Intestinal protozoan infections  
- Amoebiasis Entamoeba histolytica 
- Cryptosporidiosis Cryptosporidium hominis and C. parvum 
- Giardiasis Giardia intestinalis (syn.: G. lamblia) 
 Leishmaniasis Visceral leishmaniasis: Leishmania donovani, L. chagasi and L. infantum 
(Muco-)cutaneous leishmaniasis: L. major, L. tropica, L. braziliensis, 
L. mexicana and other Leishmania spp. 
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Neglected tropical disease Causative agent(s) 
Bacterial infections  
 Bartonellosis Bartonella henselae and other Bartonella spp. 
 Bovine tuberculosis in humans Mycobacterium bovis 
 Buruli ulcer Mycobacterium ulcerans 
 Enteric bacterial infections  
- Cholera Vibrio cholerae 
- ETEC infection Enterotoxigenic Escherichia coli (ETEC) 
- Salmonellosis Non-typhoidal salmonellosis: Salmonella enterica serovars S. Enteritidis, 
S.Typhimurium and other serovars 
Enteric fever: S.enterica serovars S. Typhi and S. Paratyphi 
- Shigellosis Shigella dysenteriae, S. boydii, S. flexneri and S. sonnei 
 Leprosy Mycobacterium leprae 
 Leptospirosis Leptospira interrogans group 
 Relapsing fever Borrelia recurrentis, Borrelia duttoni and other Borrelia spp. 
 Trachoma Chlamydia trachomatis 
 Treponematoses (bejel, pinta, syphilis, 
 yaws) 
Treponema pallidum (different subspecies) 
Fungal infections  
 Mycetoma (“Madura foot”) Various fungi (eumycetoma) and bacteria (actinomycetoma, botryomycosis) 
 Paracoccidioidomycosis Paracoccidioides brasiliensis 
Viral infections  
 Dengue Dengue fever virus (genus: Flavivirus) 
 Japanese encephalitis Japanese encephalitis virus (genus: Flavivirus) 
 Yellow fever Yellow fever virus (genus: Flavivirus) 
 Rabies Rabies virus (genus: Lyssavirus) 
 Rift valley fever Rift valley fever virus (genus: Phlebovirus) 
 Viral haemorrhagic fevers Important Arenaviridae: Lassa virus, Chapare virus, Guanarito virus, Junín 
virus, Machupo virus and Sabiá virus 
Bunyaviridae: Crimean-Congo haemorrhagic fever virus (HFV), Hanta viruses 
including Puumala virus 
Filoviridae: Ebola virus and Marburg virus 
Flaviviridae: Omsk HFV and Kyasanur forest disease virus 
Ectoparasitic infections  
 Myiasis Parasitic fly larvae (Calliphoridae, Oestridae, Sarcophagidae and others) 
 Scabies Sarcoptes scabiei 
 
The list of NTDs is rapidly evolving and it has recently been suggested to include also non-
infectious diseases such as podoconiosis, a tropical lymphoedema of the lower limb that 
occurs in farmers who are walking barefoot on soil of volcanic origin [34], and venomous 
animal contacts (e.g. snake bites) [35]. Additionally, recent research has brought to light that 
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well-known pathogens such as the bacterium Staphylococcus aureus may present in clinically 
different, often more severe disease manifestations in resource-constrained settings, and 
hence, should also be considered as neglected pathogens to which more concerted funding 
and research efforts should be directed [36,37]. 
 
1.3  Syndromic management of major health problems 
The adequate clinical management of infectious diseases is often challenging, particularly in 
the absence of accurate laboratory diagnostic techniques and if similar signs and symptoms 
are caused by a variety of infectious agents. Indeed, many gastrointestinal infections show 
substantial overlap with regard to clinical findings. In such cases, it is important to evaluate 
the patient’s condition not only from a ‘single disease’ perspective, but to consider a broad 
range of potential pathogens that may give rise to a given clinical syndrome. In clinical 
research, however, efforts frequently concentrate on one specific pathogen or disease, while 
relatively little attention is directed to syndromic approaches that take a number of potentially 
implicated causative agents into consideration. One notable exception is the approach to the 
management of sexually transmitted diseases (STDs) in resource-constrained settings [38]. 
Indeed, these infections were considered as a low priority in many resource-constrained 
settings until clinical evidence showed that effective STD management could considerably 
reduce the incidence of HIV acquisition [39]. However, it proved difficult to differentiate 
common STDs based alone on clinical findings, because signs and symptoms are often 
unspecific. Hence, well-equipped laboratories would be needed to perform diagnostic testing 
for all major implicated pathogens. However, this rather expensive approach is rarely feasible 
in rural areas of resource-constrained countries. Furthermore, mixed infections are common 
and some laboratory tests are characterised by insufficient sensitivity. Hence, a syndromic 
approach has been developed for effective STD management [40]. 
 
In a manuscript written by William K. Bosu in 1999, in which he argued to widely implement 
a syndromic STD management in resource-poor countries, the following definition was 
given: “Syndromic management implies an approach in which clinical algorithms such as 
decision trees for commonly presenting signs and symptoms (e.g. urethral discharge or 
genital ulcer) are used in case management. The symptoms selected are reasonably selected 
and easy to recognise. The algorithm provides treatment for the commonest biological causes 
of the syndrome. For example, for genital ulcer disease, treatment is provided concomitantly 
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for the two commonest causes, chancroid and syphilis, in the absence of laboratory support 
and in recognition of the limitations of clinical diagnosis” [41]. While the feasibility and 
relatively good accuracy of such a syndromic approach were confirmed in several studies 
[42-45], more recent research clearly expressed the urgent need to include at least some 
laboratory diagnostic testing parameters to establish aetiological diagnoses [46,47]. A recent 
study from Kenya, for example, showed that in a population in which laboratory diagnostic 
testing revealed a treatable STD in 32.2% of all participants, only 10.4% would have been 
identified by the syndromic, symptom-driven approach [48]. Hence, algorithms for 
syndromic management need to be continuously evaluated and adapted to the specific 
settings where they are employed. 
  
The concept of syndromic approaches for an effective management of common health 
problems has been successfully applied to other clinical entities. In 2015, Dutch researchers 
analysed the travel history, clinical and diagnostic findings of 2,153 returning travellers with 
suspected arboviral disease [49]. Many arboviral diseases, such as dengue fever, chikungunya 
fever, West Nile fever and other infections may cause very similar clinical symptoms (e.g. a 
combination of fever, rash and arthralgia) and there is substantial geographical overlap 
between many arboviral infections. However, clinicians frequently request diagnostic testing 
for only one pathogen – typically dengue virus – despite compelling evidence that clinical 
judgement alone may be unable to differentiate between the different viruses. Indeed, the 
Dutch study revealed that diagnostic testing was only seldom requested and that only half of 
patients with a history suggestive of chikungunya fever were actually tested for this infection. 
The authors concluded that clinicians should adopt a combination of a clinical “syndromic 
approach and matching laboratory methods” [49]. 
 
A syndromic approach to manage common clinical problems in an effective way has gained 
particular interest in resource-limited areas. For some infections, rapid diagnostic tests 
(RDTs) are now available that can be employed even under harsh field conditions, e.g. in 
rural areas where no diagnostic laboratory is available [50-52]. The Indian Society of Critical 
Care Medicine (ISCCM), for example, has issued new guidelines for the management of 
tropical fevers in 2014. These guidelines include easily applicable diagnostic algorithms to 
aid clinical decision-making [53]. Figure 1.1 displays such an algorithm, in which it is 
recommended to perform RDTs for malaria, dengue fever and enteric fever (typhoid) and to 
administer specific treatment in case of a positive test result. 
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Figure 1.1 A proposed algorithm for the diagnosis and treatment of critical febrile 
infections in the tropics, issued by the Indian Society of Critical Care Medicine (published in 
[53]). 
 
 
 
 
Acknowledging that many NTDs of bacterial, helminthic and protozoal origin primarily 
affect the human gastrointestinal tract in a chronic way and that specific treatment for the 
various pathogens varies considerably, it is surprising that no diagnostic algorithms for the 
management of long-lasting digestive symptomatologies have been developed thus far. From 
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a public health perspective, it may indeed be anticipated that the collective burden of 
diarrhoeal and other intestinal infections in resource-constrained tropical settings is 
considerable and the often unspecific clinical symptoms may render a syndromic approach 
much more appropriate than attempts that target a single pathogen. Hence, an international 
research consortium with the acronym NIDIAG (‘Better DIAGnosis of Neglected Infectious 
diseases’) has been initiated to develop evidence-based diagnosis-treatment algorithms for an 
improved management of three clinical syndromes in resource-constrained settings of the 
tropics and subtropics (http://www.nidiag.org). These three clinical syndromes include: (i) 
persistent digestive disorders, defined as persistent diarrhoea (≥14 days; all individuals aged 
>1 year) and/or persistent abdominal pain (≥14 days; children and adolescents aged 1-18 
years) [54]; (ii) neurological disorders [51]; and (iii) persistent fever [50,55]. The NIDIAG 
project is funded by the European Commission (EC). The current Ph.D. thesis is readily 
embedded in the NIDIAG consortium and aims at providing first data on the occurrence of 
persistent digestive disorders in resource-limited settings, associated clinical features and 
available diagnostic tests, which may contribute to the development of algorithms to improve 
the clinical management of long-lasting digestive symptomatologies in tropical and 
subtropical areas. 
 
1.4 Epidemiology, clinical features, diagnosis and treatment of selected 
pathogens 
 
1.4.1 Clostridium difficile 
C. difficile is a Gram-positive, rod-shaped, anaerobic bacterium that is capable of forming 
endospores, which may persist for long times in the environment and are resistant to most 
disinfectants that are used in hospital settings [56,57]. C. difficile is the leading cause of 
nosocomial diarrhoea in high-income countries and has recently also been identified in a 
considerable number of patients with community-acquired diarrhoeal diseases [58]. Disease 
manifestations may vary from asymptomatic or mild diarrhoea to pseudomembranous colitis 
and potentially fatal complications, e.g. toxic megacolon [59]. According to the GBD 2013 
study, C. difficile accounts for half of all diarrhoea-associated deaths in high-income 
countries and almost all deaths due to diarrhoea in elderly people [6]. While the importance 
of C. difficile infection (CDI) has been acknowledged in high-income countries and efforts 
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are underway to improve diagnosis and treatment, the epidemiology, burden and clinical 
features of this infection are poorly understood in most parts of the developing world. While 
some studies from large hospitals in Asia (e.g. in Shanghai) reported a low incidence of CDI 
[60,61], researchers from the Philippines identified C. difficile in 44% of patients who had 
been investigated for colitis [62]. In Latin America, recent data suggest that the burden due to 
C. difficile might also be considerable, and some epidemic strains are now widespread in 
various, geographically very diverse areas such as Costa Rica and Chile [63,64]. In contrast, 
almost no data are available on the occurrence of C. difficile and the circulating strains in 
sub-Saharan Africa. 
 
C. difficile colonises the colon of humans and animals and can thus be found in the normal, 
healthy population. A recent study reported a carriage rate of 8% in newly admitted hospital 
patients in North America [65] and a meta-analysis revealed that 14.8% of all individuals 
living in long-term care facilities are temporarily colonised with C. difficile [66]. The 
bacterium may produce an enterotoxin (toxin A) and a cytotoxin (toxin B), which account for 
most of the morbidity. Strains can be differentiated by molecular methods (e.g. polymerase 
chain reaction (PCR) ribotyping) and some strains, such as the ribotype 027, are considered 
as ‘hypervirulent’ and may cause a more severe clinical course of disease [67]. In addition to 
toxins A and B, these hypervirulent strains produce a binary toxin and are characterised by 
typical mutations in the toxin repressor gene tcdC, which in turn lead to a hyperproduction of 
toxins A and B. There are also non-toxigenic C. difficile strains, but these are unable to cause 
disease. The amount of toxins that is produced by C. difficile after ingestion of either 
endospores or vegetative bacteria via the faecal-oral route is also influenced by the presence 
of physiological intestinal flora. It is a common adverse event of antibiotic treatment to 
disrupt this protective flora, and hence, previous antibiotic treatment is one of the most 
important risk factors for developing CDI [68]. Age >65 years, residency in a nursing home, 
medical gastric acid suppression (e.g. use of proton pump inhibitors) and immunosuppression 
are further risk factors [56]. 
 
Asymptomatic carriage of C. difficile (both toxigenic and non-toxigenic strains) is common, 
particularly in hospitalised patients [65]. Hence, no treatment should be initiated in the 
absence of clinical symptoms. If symptoms are present, these may range from watery 
diarrhoea, frequently accompanied by a foul odour, to severe diarrhoea with accompanying 
exsiccosis and pseudomembranous colitis (Figure 1.2) [61]. Some patients develop severe 
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and potentially life-threatening complications such as ileus, toxic megacolon, intestinal 
perforation and subsequent C. difficile bacteraemia. In these patients, a massively elevated 
leukocyte count and high fever may be observed and the diarrhoea may suddenly change to 
constipation. Rapid consultation with a visceral surgeon is important to consider life-saving 
surgical interventions in these patients [57]. 
 
Figure 1.2 Typical morphology of pseudomembranous colitis due to severe C. difficile 
infection, visualised during diagnostic colonoscopy (published in [61]). 
 
 
The first step to establish the diagnosis of CDI in the laboratory is typically the application of 
a stool-based screening test, i.e. an RDT detecting a C. difficile-specific glutamate 
dehydrogenase (GDH). The test is highly sensitive and has a high negative predictive value 
(NPV), thus no further testing is required if the GDH RDT is negative. If the screening test is 
positive, this proves the presence of C. difficile, but a confirmation test is required to 
differentiate toxin-producing, pathogenic strains from non-toxigenic, apathogenic strains. 
Hence, either an enzyme immunoassay detecting toxins A and B or a PCR assay targeting the 
respective toxin genes is required to identify the toxigenic strains. The sensitivity of enzyme 
immunoassays for toxin detection is limited, and PCR should thus preferably be employed as 
confirmation test [56]. However, it is important to note that PCR is only able to detect the 
toxin genes, but cannot reliably predict whether these are actually transcribed and translated 
into toxins. Anaerobic toxigenic culture is considered the diagnostic ‘gold’ standard, but it is 
not routinely performed in most microbiology laboratories and takes at least 3 days to 
generate first results. In case of detection of toxigenic C. difficile isolates, further molecular 
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typing methods can be employed. PCR ribotyping is the most important method and it allows 
to identify strains of particular importance, e.g. the hypervirulent RT027, which is now 
widespread across many parts of Europe [69], and RT078, which might be transmissible 
between humans and animals as a zoonotic strain and is associated with community-acquired 
CDI [70]. An accurate diagnosis of CDI remains challenging, even in high-income countries. 
A recent European multi-country study estimated that approximately 40,000 hospitalised 
patients with symptomatic C. difficile infection remain untreated every year in Europe due to 
the use of insufficiently sensitive diagnostics [71]. 
 
For mild C. difficile infections that occur during or shortly after antibiotic treatment, no 
specific treatment may be necessary and it can be sufficient to stop the antibiotic medication 
[57]. However, if a specific agent is required to treat CDI, oral metronidazole for 10 
consecutive days is the preferred agent. In severe disease or for the treatment of the 
frequently occurring relapses, the glycopeptide vancomycin is superior to metronidazole. In 
case of multiple relapses and no improvement following treatment with both agents, 
fidaxomicin is the recommended treatment [72]. Some patients do not respond to antibiotic 
treatment or develop multiple relapses shortly after stopping the medication. In these patients, 
‘faecal microbiota transfer’ or ‘stool transplantation’ (i.e. the transfer of the intestinal flora of 
a healthy donor to a symptomatic patient) has been reported to be highly efficacious. Indeed, 
there is growing evidence from several case series and randomised controlled trials reporting 
high cure rates associated with this treatment modality [73]. As clinical experience with this 
faecal microbiota transfer in daily clinical practice is still limited, though, it should currently 
only be performed in specialised centres [74]. 
 
1.4.2 Schistosoma mansoni 
There are six different blood flukes (trematodes) of the genus Schistosoma that are able to 
cause human disease, i.e. S. mansoni, S. haematobium, S. japonicum, S. intercalatum, 
S. mekongi and S. guineensis [23,75]. The latter three species are only of limited importance 
in some distinct foci of the world, while S. japonicum is of particular health relevance in the 
People’s Republic of China and the Philippines [24]. Most of the disease burden worldwide is 
caused by the remaining two species, S. haematobium and S. mansoni. Both species are 
endemic across large parts of sub-Saharan Africa, North Africa, the Arabian peninsula and 
the Middle East [76]. S. mansoni also occurs in Brazil and some parts of Central America 
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(Figure 1.3). Recently, autochthonous cases of S. haematobium infection have been reported 
from Corsica and experts warn that schistosomiasis might potentially become also a 
European disease [77-79]. The GBD 2010 study estimated the schistosomiasis-associated 
disease burden to be as high as 3.3 million DALYs, with up to 250 million individuals 
infected. Hence, schistosomiasis is one of the most important NTDs. School-aged children 
and adolescents are considered at highest risk of infection and morbidity, but more recent 
research has also elucidated the substantial burden of schistosomiasis in infants and 
preschool-aged children (<5 years of age) as well as in adults [75,80-82]. 
 
Figure 1.3 The global distribution of schistosomiasis, stratified by infecting species 
(adapted from [24]). 
 
 
 
Schistosomiasis is a water-based parasitic disease, which can be explained by the parasite’s 
life cycle [23,24]. The adult female and male worms live in permanent pairs inside the human 
host, where they reside in the perivesical (S. haematobium) or portal and mesenteric blood 
vessels (S. mansoni and other species). The female worms produce up to several thousand 
eggs per day, which either get trapped in host tissue (e.g. liver and bladder), where they can 
induce considerable inflammation, or reach the bladder (S. haematobium) or intestine 
(S. mansoni), respectively, from where they are excreted with urine or faeces. If the eggs get 
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in contact with freshwater, the miracidium, a first stage larva, hatches from the eggs. For its 
further development into a larva that is able to infect humans, a second development step is 
required within specific freshwater snails that serve as intermediate hosts (e.g. 
Biomphalaria spp. in case of S. mansoni) [83]. Following asexual replication in the snail, so-
called cercariae are released into the water, which are able to infect humans through the intact 
skin, e.g. during swimming or bathing activities in an infested lake. After the transcutaneous 
penetration, cercariae are transported hematogenously to the lungs and further onwards to the 
liver, where they develop into adult worms, before they migrate to their final destination 
where they start to produce eggs. This life cycle explains the very focal distribution of 
schistosomiasis, because freshwater bodies infested with suitable intermediate hosts are a 
necessity without which the helminth could not maintain its development cycle. 
 
S. mansoni is the main aetiological agent of intestinal schistosomiasis, while S. haematobium 
causes genitourinary schistosomiasis. Some weeks after the first infection, an acute disease 
characterised by sudden headache, fever, myalgia and elevated peripheral eosinophilia, also 
termed as Katayama syndrome, may occur and reflects the systemic immune reaction to the 
infection. It is frequently seen in returning travellers, but is rare in populations living in 
endemic areas [75]. In general, Schistosoma-related morbidity is not caused by the adult 
worms, but rather by the produced eggs that frequently get trapped in host tissues [24]. In the 
case of S. mansoni infection, abdominal tenderness, diarrhoea, pain and abdominal 
discomfort and blood in the stool constitute common symptoms and clinical findings [84,85]. 
In some individuals, extensive periportal fibrosis may develop, with subsequent 
hepatosplenic disease, splenomegaly and portal hypertension [86]. Aberrant oviposition of 
Schistosoma eggs in other organs may lead to further complications, e.g. 
neuroschistosomiasis with subsequent paralysis if eggs are deposited into the central nervous 
system. It is now widely acknowledged that even individuals with light infection intensities 
and apparently ‘asymptomatic’ schistosomiasis suffer from long-term morbidity such as 
anaemia, impaired cognitive development and malnutrition [87]. 
 
The laboratory diagnosis of S. mansoni infection relies on the detection of helminth eggs in 
the faeces (or biopsies of affected tissues) [76]. Several microscopic techniques are available, 
such as direct faecal smear, Kato-Katz technique, FLOTAC, Mini-FLOTAC and the 
formalin-ether concentration technique [88]. Following WHO recommendations, the Kato-
Katz technique is widely used in endemic settings [89]. However, infections of light intensity 
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(i.e. with few eggs shed per gram of stool in the faeces) are easily missed by all microscopic 
methods. More recently, a point-of-care (POC) RDT has been developed; it takes advantage 
of the fact that schistosomes excrete a circulating cathodic antigen (CCA) which can be 
detected in the serum and urine of an infected host. A urine-based POC-CCA test is now 
commercially available and showed a higher sensitivity than microscopy using the Kato-Katz 
technique in several African countries [90]. However, it remains to be elucidated how this 
test performs in a clinical setting and whether it can be used for individual patient 
management. PCR techniques have also been developed and show a much higher diagnostic 
accuracy than standard microscopy [91]. While molecular PCR techniques are increasingly 
being used in epidemiological studies and European reference laboratories, they have not yet 
found their way into daily clinical practice and it is unlikely that this will happen in the near 
future in those resource-constrained settings where the burden of schistosomiasis is highest. 
Serology is a helpful tool in returning travellers and can be used in epidemiological studies, 
e.g. to monitor populations in areas where schistosomiasis elimination is about to be achieved 
[76]. 
 
Once the diagnosis of schistosomiasis is established, oral treatment with praziquantel is 
highly efficacious and generally well-tolerated [92]. Besides its use for individual patient 
management, praziquantel is also used for ‘preventive chemotherapy’, i.e. a control 
programme recommended by WHO that consists of annual or bi-annual administration of 
praziquantel to all school-aged children living in highly endemic areas through teachers or 
community health workers [93]. While such regular mass drug administration (MDA) is not 
sufficient to eliminate schistosomiasis from these settings (re-infections may rapidly occur), 
morbidity is, however, greatly reduced through averting high-intensity infections with e.g. 
subsequent periportal fibrosis. In 2012, the World Health Assembley resolution 65.19 called 
for intensified efforts to achieve elimination of schistosomiasis in selected countries in the 
near future. Various activities and initiatives are underway to investigate the best approach to 
achieve elimination, i.e. preventive chemotherapy, improved sanitation and hygiene, 
behaviour change, snail control (i.e. through the use of molluscicides) and improved 
diagnostics [94,95]. 
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1.4.3 Strongyloides stercoralis 
The threadworm Strongyloides stercoralis is a nematode that occurs in tropical and 
subtropical areas [96]. Its epidemiology, distribution and clinical features are much less 
understood than those of the three major soil-transmitted helminths (Ascaris lumbricoides, 
Trichuris trichiura and the two hookworm species Ancylostoma duodenale and Necator 
americanus). The life cycle of S. stercoralis is complex and comprises two specific 
characteristics, i.e. autoinfection and hyperinfection [97,98]. The adult worms reside in the 
gastrointestinal tract of the human host and produce eggs, which hatch already inside the 
host. Hence, first-stage (L1) larvae are passed with the faeces and may contaminate the soil in 
areas of poor sanitation. In case of appropriate environmental conditions (temperature, 
humidity), the rhabditiform L1 larvae can develop within the soil into infective, filariform L3 
larvae that may penetrate intact human skin, e.g. when walking barefoot on contaminated 
soil. Following the penetration of the skin, the larvae may travel hematogenously to the 
lungs, where they can get into the alveolar spaces and migrate upwards to the pharyngeal 
area. Once arrived there, the small larvae are unconsciously swallowed to be transported into 
the intestine, where they develop into adult worms and start egg production [8]. 
 
The so-called autoinfection is a characteristic of S. stercoralis, which distinguishes it from 
almost all other helminths that infest humans (with the exception of Capillaria spp.) [99]. 
Indeed, some L1 larvae that hatch in the intestine are not passed with the faeces, but may 
develop inside the human host into filariform L3 larvae that can penetrate the intestinal 
mucosa and spread throughout the body. In immunocompetent individuals, no symptoms may 
be associated with such an autoinfection, but the internal replication permits the helminth to 
maintain infections within the same host for decades [8,98]. In case of immunosuppression 
(e.g. malignant diseases, corticosteroid treatment, co-infection with retroviruses and organ 
transplantation), the host’s immune system may lose its ability to control an existing 
intestinal S. stercoralis infection. The helminth larvae may start to rapidly replicate and 
spread throughout the body, thereby causing a frequently fatal sepsis-like condition, the so-
called hyperinfection syndrome [100].  
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Figure 1.4 The life cycle of S. stercoralis (published in [8] after being adapted from [101]).  
  
 
Due to its potential to cause severe hyperinfection in patients after many years of 
asymptomatic infection, S. stercoralis should always be included in the differential diagnosis 
if a patient has ever travelled to an endemic area. Resource-constrained settings in tropical 
countries are typically considered to be endemic for S. stercoralis [102], but the helminth 
may also cause infections in high-income countries such as parts of the United States of 
America [103] and Italy [104]. The global burden of strongyloidiasis is ill-defined and 
scientific estimates range between 30 million and more than 370 million infected people 
worldwide [105]. The autoinfectious cycle with the potential life-long persistence of infection 
and the risk of developing hyperinfection make it necessary to treat every patient with a 
diagnosed strongyloidiasis, regardless of his/her current symptoms [8]. 
 
The clinical features of strongyloidiasis are manifold and seem to be related to the intensity 
of infection. While many individuals are infected asymptomatically, diarrhoea, abdominal 
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tenderness, weight loss and bloating are also commonly reported [18]. When the larvae 
migrate through the body, fast-moving cutaneous itchy eruptions called “larva currens” may 
sometimes be seen. The larval transition through the lungs may lead to persistent cough 
and/or wheezing on pulmonary auscultation. Peripheral blood eosinophilia may be present, 
but its absence does not rule out the possibility of strongyloidiasis, particularly in severely ill 
patients with a suspected hyperinfection syndrome [106]. 
 
The visualisation of S. stercoralis in human stool specimens is particularly challenging 
because no eggs are passed into the faeces and the most commonly employed microscopic 
techniques for intestinal parasites frequently fail to detect the L1 larvae [107]. Hence, more 
laborious and time-consuming methods need to be employed, such as the Baermann funnel 
concentration technique or nutrient agar plate cultures (e.g. Koga agar plate) [108,109]. 
Ideally, two microscopic techniques should be combined and several consecutive stool 
specimens should be examined to achieve a high diagnostic accuracy. Stool-based PCR 
assays have been developed and hold promise for an improved diagnosis of S. stercoralis, but 
require further validation in areas of endemicity [110]. Outside endemic settings, serology is 
a very valuable tool to evaluate patients for strongyloidiasis, because anti-Strongyloides 
antibody detection is highly sensitive (with the exception of severely immunocompromised 
patients) and decreasing antibody titres can also be used to monitor the treatment response 
[111]. Ivermectin is the preferred and most efficacious treatment against strongyloidiasis, 
whereas albendazole and mebendazole fail to cure the disease in a considerable amount of 
patients [112,113]. 
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2 Goal and specific objectives 
The overarching goal of this Ph.D. thesis was to deepen the understanding of the occurrence 
of persistent diarrhoea (≥14 days) and persistent abdominal pain (≥14 days) in resource-
constrained settings, to elucidate the spectrum of causative infectious agents and associated 
clinical disease manifestations, and to contribute to the development of an evidence-based 
algorithm for a syndromic management of persistent digestive disorders. Five specific 
objectives were related to this goal. 
 
1. To review bacterial, parasitic and viral pathogens that may give rise to persistent digestive 
disorders in the tropics and subtropics. 
2. To develop a standardised protocol to investigate persistent digestive disorders (≥14 days) 
in a multi-country study, comprising a comprehensive clinical assessment and detailed 
laboratory investigations. 
3. To investigate the prevalence of multiple intestinal pathogens in symptomatic patients 
with persistent diarrhoea (≥14 days) and healthy controls in south Côte d’Ivoire. 
4. To evaluate multiplex PCR assays for the diagnosis of intestinal pathogens in a tropical 
setting and to compare the diagnostic accuracy of PCR, RDTs and standard diagnostic 
tools for selected pathogens, specifically C. difficile, Cryptosporidium spp., 
G. intestinalis, S. mansoni and S. stercoralis. 
5. To describe the clinical signs and symptoms associated with the occurrence of specific 
intestinal pathogens and to synthesise clinical and microbiological data for the 
development of an evidence-based diagnosis-treatment algorithm pertaining to the 
management of persistent digestive disorders (≥14 days) in resource-limited tropical 
settings.
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Persistent digestive disorders can be defined as any diarrhea (i.e., three or more loose stools 
per day) lasting for at least 2 weeks and/or abdominal pain that persists for 2 weeks or longer 
[1-3]. These disorders cause considerable morbidity and human suffering, and hence, are 
reasons why people might seek primary health care. However, in resource-constrained 
settings of the tropics and subtropics, accurate point-of-care diagnostics are often lacking and 
treatment is empiric, particularly in remote rural areas with no laboratory infrastructure. As a 
result, the relative contribution of selected pathogens to the syndrome of persistent digestive 
disorders is poorly understood, and evidence-based guidelines for patient management in 
different social-ecological settings are scarce [4-6]. 
In order to improve the clinical management of patients with persistent digestive 
disorders stemming from neglected tropical diseases (NTDs), the European Commission (EC) 
funded a 5-year study – the NIDIAG research consortium. The overarching goal of the 
NIDIAG consortium is to develop and validate patient-centered diagnosis-treatment 
guidelines for use at the primary health care level in low- and middle-income countries 
(http://www.nidiag.org) [3,7-9]. Emphasis is placed on three syndromes: (i) persistent 
digestive disorders described here; (ii) persistent fever; and (iii) neurological disorders that 
latter two of which are detailed in companion pieces published in the same issue of PLoS 
Neglected Tropical Diseases. 
With regard to the study on persistent digestive disorders, the main aims are (i) to identify 
the most important NTDs and other infectious agents that give rise to this clinical syndrome, 
including their relative frequency; (ii) to assess and compare the accuracy of different 
diagnostic methods; and (iii) to determine clinical responses to commonly employed empiric 
treatment options for persistent digestive disorders [9]. To this end, a case-control study has 
been implemented in four countries; Côte d’Ivoire and Mali in West Africa, and Indonesia 
and Nepal in Asia. An integral part of the NIDIAG consortium is to ensure that good clinical 
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practice (GCP) and good clinical laboratory practice (GCLP) are adhered to during the 
conduct of the studies [10,11]. A quality assurance system, which included the development 
and implementation of a set of standard operating procedures (SOPs), along with on-the-spot 
staff training and internal and external quality control activities, has been developed at project 
level, and introduced at each study site. The development and adherence to SOPs within 
harmonized study protocols were considered crucial steps for maximizing integrity of 
laboratory and clinical data across study settings. It also provided the basis on which quality 
control activities could be performed. 
 
For Which Procedures Have SOPs Been Developed? 
For the study on persistent digestive disorders, 33 specific SOPs have been developed 
(Supporting Information, S1-S33). As summarized in Table 1, detailed steps on clinical and 
laboratory procedures, data management, and quality assurance were described. With regard 
to clinical investigations, SOPs on history taking and clinical examination, assessing inclusion 
and exclusion criteria, patient recruitment, and study flow were developed (S1-S6). Detailed 
instructions on how to perform a set of laboratory diagnostic techniques for the detection of 
helminth and intestinal protozoa infections were included in the laboratory SOPs. Different 
conventional stool microscopy techniques were combined with more recent rapid antigen 
detection tests to encompass a broad spectrum of potentially implicated pathogens with high 
diagnostic accuracy (S7-S20). An overview of the employed diagnostic methods is provided 
in Table 2. Pertaining to data management, SOPs on completion of case report forms (CRFs) 
and on its various activities (such as data entry, data cleaning, querying, database locking, and 
backing up data) were also included. To ensure quality control, SOPs on internal quality 
control activities, external monitoring, and laboratory supervision visits were jointly 
developed for the three syndromes (S21-S33). 
  
Table 1. Set of standard operating procedures (SOPs) used in the NIDIAG study on persistent digestive disorders. 
 
Number Type Purpose of SOP End user Syndrome 
1 Clinical History taking Site investigator Digestive 
2 Clinical Clinical examination Site investigator Digestive 
3 Clinical Selection of controls without digestive syndrome Site investigator Digestive 
4 Clinical Specific treatment procedures (including dosage) Site investigator Digestive 
5 Clinical Assessing inclusion and exclusion criteria Site investigator Digestive 
6 Clinical Patient recruitment and patient flow Site investigator Digestive 
7 Laboratory Kinyoun staining technique Laboratory technician Digestive 
8 Laboratory Modified acid-fast staining technique Laboratory technician Digestive 
9 Laboratory Crypto/Giardia Duo-Strip rapid diagnostic test (RDT) Laboratory technician Digestive 
10 Laboratory Kato-Katz technique Laboratory technician Digestive 
11 Laboratory Baermann technique Laboratory technician Digestive 
12 Laboratory Mini-FLOTAC technique Laboratory technician Digestive 
13 Laboratory How to obtain a stool sample Laboratory technician Digestive 
  
14 Laboratory Formalin-ether concentration technique Laboratory technician Digestive 
15 Laboratory Koga agar plate culture Laboratory technician Digestive 
16 Laboratory Direct fecal smear technique Laboratory technician Digestive 
17 Laboratory Preparation of aliquots for molecular post-hoc testing Laboratory technician Digestive 
18 Laboratory Urine point-of-care circulating cathodic antigen (POC-CCA) RDT for 
the diagnosis of Schistosoma mansoni 
Laboratory technician Digestive 
19 Laboratory Diagnostic sample flow Laboratory technician Digestive 
20 Laboratory Urine sampling Laboratory technician Digestive 
21 Quality  Obtaining informed consent Site investigator Common 
22 Quality Numbering system to be used in NIDIAG studies Laboratory technician Digestive 
mainly 
23 Quality  Management of study documents Principal investigator 
(PI)/site investigator/ 
nurse/laboratory 
technician 
Common 
24 Quality SOP on SOP SOP author Common 
  
25 Quality External monitoring PI/site investigator Common 
26 Quality Internal quality control activities Quality manager Common 
27 Quality Good clinical laboratory practice (GCLP) supervision visits Quality manager Common 
28 Quality Min/max thermometer Laboratory technician Common 
29 Quality Stock management Laboratory technician Common 
30 Quality Handling of expired and disqualified products Laboratory technician Common 
31 Quality Handling and storage of rapid diagnostic tests Laboratory technician Digestive 
32 Data Completing case report forms (CRFs) Site investigator Common 
33 Data Procedure for data management Data manager Digestive 
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Table 2. Laboratory diagnostic techniques used and internally compared in the NIDIAG 
study on persistent digestive disorders. 
 
Diagnostic technique Target pathogen(s) 
 Soil-transmitted 
helminths 
Schistosoma 
mansoni 
Strongyloides 
stercoralis 
Intestinal 
protozoa 
Direct fecal smear ( ) ( ) ( ) ( ) 
Kato-Katz technique   – – 
Formalin-ether concentration 
technique 
  ( )  
Mini-FLOTAC   – ( )
a
 
Baermann technique ( )
b
 –  – 
Koga agar plate culture ( )
b
 –  – 
Rapid diagnostic test for 
Cryptosporidium and Giardia 
intestinalis 
– – – c 
Point-of-care circulating 
cathodic antigen (POC-CCA) 
urine cassette test 
–  – – 
Acid-fast staining procedure – – – d 
The laboratory diagnostic techniques consisted of microscopic methods and rapid diagnostic 
tests (RDTs). They were used and compared within the NIDIAG study on persistent digestive 
disorders, placing particular emphasis on the suitability for the detection of helminths and 
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intestinal protozoa that may give rise to persistent digestive disorders (≥2 weeks). The following 
grading system was employed to characterize the suitability of a certain laboratory technique for 
the detection of specific pathogens: : suitable; ( ): partially suitable; –: not suitable.  
Of note, additional bacteriologic stool cultures were performed in all countries except Indonesia 
in case of diarrheic stool samples. 
a 
Very limited published data, according to which FLOTAC techniques may detect some 
intestinal protozoa species (e.g., G. intestinalis), but further validation of the technique for this 
use is required. 
b
 Hookworm larvae can be detected, in particular by culture. Additionally, hookworm larvae can 
be found using the Baermann technique, if the stool sample has been kept long enough for the 
eggs to hatch. 
c
 This RDT detects only Cryptosporidium spp. and G. intestinalis. 
d
 Acid-fast staining methods (e.g., Kinyoun stain) are particularly suitable for the detection of 
Cryptosporidium spp., Cyclospora cayetanensis, and Cystoisospora belli that are easily missed 
by most other microscopic diagnostic techniques. 
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Of note, all SOPs were developed in English (for use in Nepal) and subsequently translated 
into French (for use in Côte d’Ivoire and Mali) and Bahasa Indonesia (for use in Indonesia). This 
comprehensive set of closely interconnected SOPs, which provides guidance on all essential 
procedures from the first presentation of an individual at a health care center until the final 
processing of all patient and laboratory data, is displayed in Fig 1. 
 
Fig 1. Principal elements of the NIDIAG digestive study and the respective standard 
operating procedures (SOPs) used. 
 
 
Chapter 5: Experiences from a multi-country study on persistent digestive disorders  
 
 
__________ 
84 
 
How Was the Development of SOPs Coordinated, and Which Quality Control 
Measures Were Adopted? 
The development and harmonization of the various SOPs was coordinated by the quality 
assurance group of the NIDIAG consortium and the trial management group (TMG) of the 
digestive syndrome study, and followed a standard template and consortium-wide guidelines 
stipulated in the SOP entitled “SOP on SOP” (S24). This allowed different authors with varied 
background and writing styles to convey key messages and pass on their expert knowledge in a 
systematic, standardized manner for the benefit of the end-user of all the SOPs. In addition, it 
provided clear instructions on how the SOPs should be numbered, reviewed, and approved to 
allow for strict version control. The authors of the SOPs were chosen from within the NIDIAG 
consortium and allocation of topics was based on expertise and track record in the clinical, 
laboratory, data management, and quality assurance components of the study. Experts in the 
field, at the bench, and at the bedside carefully reviewed and revised the draft SOPs. Before the 
start of recruitment, local clinical and laboratory teams were trained on the set of SOPs through 
two hands-on workshops lasting three days each, conducted on site by relevant experts of the 
NIDIAG consortium. During these workshops, feedback from the local partners was 
incorporated to refine the already developed SOPs, and additional SOPs were jointly developed 
to meet specific demands of local clinical, epidemiologic, and laboratory conditions. For 
example, in Indonesia, where Kinyoun staining was not available, an SOP pertaining to a slightly 
modified acid-fast staining technique was developed for the local team instead. Finally, once an 
SOP was finalized, a member of the TMG would approve it. A quality assurance member of the 
NIDIAG consortium was tasked to compile and keep updated the final set of SOPs and ensure 
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that the latest versions were available on the NIDIAG Intranet for distribution among the 
different country partners. 
 
Which Patient Recruitment Patterns Have Been Observed? 
In clinical trials and case-control studies, it is one of the most difficult tasks to precisely define 
patient inclusion and exclusion criteria, and to carry out the enrolment accordingly under ‘real 
life’ conditions, thereby minimizing selection bias [12]. Apart from a specific study protocol and 
a given research question, several studies have shown that many internal and external factors 
may considerably influence the pace of patient recruitment in clinical trials, many of which are 
not related to scientific issues, such as, for example, the workload for study staff who are 
responsible for the recruitment of patients, the distance between the study center, and the place 
of residence of potential participants, insufficient engagement with the community, and the 
complexity of consent procedures prior to the start of a trial [13,14]. In the NIDIAG study 
pertaining to persistent digestive disorders, several site assessments were carried out in the four 
countries before launching the larger multi-country study [15]. It was decided that a case-control 
design should be adopted [16-18] and that the ideal target sample size in each country would be 
in the range of 500 symptomatic patients and 500 asymptomatic controls. After obtaining all the 
necessary ethics approvals (August 2013 – January 2014), considerable study document and site 
preparations, and GCP/GCLP training of the study site staff, the first patient was recruited in 
Nepal on July 30, 2014. 
Interestingly, the recruitment of patients and controls showed considerable heterogeneity 
across countries. Fig 2 displays the country-specific enrolment over time. In Mali, where almost 
exclusively patients with persistent abdominal pain (and very few with persistent diarrhea) were 
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recruited, the numbers of eligible patients and controls were high, and the recruitment went 
smoothly and without major obstacles. Indeed, a total of 553 patients and 553 matched controls 
were enrolled by May 2015, when the study deemed successfully completed in Mali. 
 
Fig 2. Country-specific enrolment characteristics of patients and controls in the NIDIAG 
study on persistent digestive disorders. 
 
 
A different pattern was observed in Nepal. Patient recruitment started well in July and 
August 2014, but was temporarily interrupted for a period of almost 3 months due to protracted 
strikes and civil unrest that limited freedom of movement of the people. Later, patient enrolment 
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resumed at a stable recruitment pace (with some seasonality seen) until August 2015, when 
nation-wide strikes again affected the number of enrolled patients, so that the initially targeted 
sample size of 500 symptomatic patients and 500 controls could not be reached. 
A slow recruitment rate was observed in Côte d’Ivoire during the first months of the study, 
which was mainly explained by the fact that few eligible patients presented to the study hospital, 
whereas higher numbers of patients with either persistent abdominal pain or persistent abdominal 
pain were reported from rural, remote health care posts in the surroundings of the study hospital. 
Hence, the recruitment was changed from a mainly passive approach, i.e., waiting for 
symptomatic patients to present to the study hospital, to a more pro-active enrolment strategy, 
which included information of health care workers in the peripheral health care institutions and 
villages about the purpose and scope of the study, so that they could actively refer potentially 
eligible patients to the study team. 
A similar pro-active approach was adopted in Indonesia, but the number of enrolled patients 
with persistent digestive disorders remained very low. Hence, after 5 months (August 2014 – 
January 2015), it was decided by the study country team and the TMG to interrupt the study 
prematurely and to modify the design. Subsequently, a large community-based survey was 
carried out in the study area, which employed the same suite of diagnostic methods as foreseen 
in the original study protocol, to improve the diagnosis of parasitic infections, and to increase the 
understanding of the causes and the clinical features that are related to these infections in rural 
Indonesia. The respective ethics committees were readily informed about the necessary 
modifications and approval was obtained before the start of the survey. 
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What Were Key Challenges During Patient Recruitment? 
During the conduct of the NIDIAG digestive study, several challenges were encountered that 
underscore why it remains an ambitious goal to perform studies on neglected clinical syndromes 
in the tropics. First, most study investigators reported difficulties in recruiting patients with 
persistent diarrhea as defined by the World Health Organization (WHO), i.e., any diarrhea 
lasting for at least 14 days [2]. Indeed, while long-lasting diarrheal diseases were perceived as a 
relevant clinical problem in all four study countries, many patients with persistent diarrhea had 
previously either taken empiric treatment (i.e., antibiotics, antiparasitics, or traditional 
medicines) or consulted a health care professional (e.g., village health center or local pharmacy). 
In this context, it is important to note that anti-diarrheal medication and anti-infective drugs are 
regularly available as over-the-counter drugs without prescription in many low- and middle-
income countries, and are thus easily accessible [19,20]. Such medical and pharmaceutical 
interventions probably led to partial, transitory improvement in some patients, but the digestive 
symptoms returned after variable periods of intermittence in a considerable proportion of study 
participants. However, such patients frequently failed to meet the actual inclusion criteria 
because the onset of diarrheal symptoms after 2 days without diarrhea was defined as a new 
episode [9], and some of them could thus not be included. 
Second, diarrhea and abdominal pain are relatively vague, while subjective symptoms and 
their reported severity depends on the perceived concepts of illness of the individual patient [21]. 
Previous studies have shown that the length of the recall period is inversely related to the 
accuracy and reliability of reported patient complaints and that less severe episodes of diarrhea 
can be up to 40% underreported with a recall period of one week [22]. Furthermore, there is 
evidence from resource-constrained settings that diarrhea is less likely to be reported as a 
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perceived health problem if it is common in a specific area [23,24]. For obvious reasons, 
‘persistent abdominal pain’ is even more difficult to define and to objectively retrace. The 
application of a standardized medical examination as part of the routine work-up in the NIDIAG 
digestive study was thus considered an essential tool to complement data gathering and to 
counterbalance inaccuracies obtained by self-assessed morbidity reports. Third, the NIDIAG 
digestive study was non-interventional and study site-specific factors had thus to be considered. 
In Nepal, for instance, there are considerable government-run mass drug administration (MDA) 
campaigns that may have led to a decrease of helminthiasis-associated diarrheal diseases. Indeed, 
bi-annual deworming with albendazole for children aged 12-59 months has been carried out 
along with vitamin A supplementation since 1999, and albendazole is given twice a year to 
children attending grades 1-10 of all public and private schools. Albendazole has also been 
administered since 2005 along with diethylcarbamazine citrate (DEC) as part of the efforts to 
eliminate lymphatic filariasis and Nepal is expected to complete six rounds of MDA in 2018. 
Finally, pregnant women are also given albendazole during their second trimester. Hence, nearly 
all age groups in Nepal may potentially receive this anthelmintic drug through one of these MDA 
campaigns, and it will be interesting to see whether the NIDIAG study results confirm a 
beneficial effect on helminth-associated persistent digestive disorders. 
Fourth, the etiology of persistent diarrhea and persistent abdominal pain is manifold and not 
limited to infectious causes. Autoimmune disorders, inflammatory diseases, neoplasms and 
specific food intolerances may, among others, also lead to persistent intestinal disorders [25]. 
The researchers and clinicians on site experienced that this fact needs to be explained in detail to 
symptomatic patients without an identified pathogen, and further investigations or referral to 
additional diagnostics should be initiated promptly. Of note, the detection of a certain pathogen 
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in a stool or urine sample does not necessarily mean that the patient’s symptoms are actually 
linked to this finding [26]. As the proportion and quantity of encountered pathogens may vary 
considerably from one setting to another, the NIDIAG study employed a case-control approach 
to elucidate pathogen-specific attributable fractions to the syndrome of persistent digestive 
disorders [27,28]. 
Controls were recruited from the same study centers as the symptomatic patients and were 
further matched by age groups and sex to the symptomatic cases. It proved to be difficult to 
obtain consent of individuals to act as controls because they were frequently wondering why 
someone would be interested in analyzing stool and urine samples of healthy individuals. While 
careful explanation – being particularly sensitive to potential cultural barriers – helped to clarify 
this, some individuals still considered stool samples as very personal, intimate specimens, and 
refused to participate. Indeed, the Nepalese study sites observed that it was very difficult to 
include asymptomatic patients who were unrelated to a symptomatic patient, while it was 
relatively straightforward to obtain consent from friends, relatives, or neighbors of symptomatic 
cases with persistent diarrhea, potentially because these individuals shared similar exposure 
characteristics (e.g., source of drinking water) with the symptomatic patient and wanted to know 
whether they were found to carry the same intestinal pathogens. 
 
Have Challenges of Specific Laboratory Techniques Been Observed, and 
Which Solutions Have Been Adopted? 
Two main areas of laboratory-associated challenges were identified during the NIDIAG 
digestive study, i.e., pertaining to (i) general infrastructure and equipment; and (ii) the conduct of 
the diagnostic laboratory tests. First, it was noted during the pre-study field visits that the 
Chapter 5: Experiences from a multi-country study on persistent digestive disorders  
 
 
__________ 
91 
 
available laboratory infrastructure in the study countries was – at most sites – not sufficient to 
accommodate such a broad diagnostic test panel as indicated by the NIDIAG study protocol [3]. 
Indeed, there was no laboratory that had routinely employed all of the methods before the onset 
of the study. Hence, workshops were held to familiarize study staff with the techniques and to 
harmonize procedures across study countries. Additionally, many efforts were required to 
establish an internal and external quality assurance and monitoring system, so that GCP/GCLP 
standards were met. It is important to note that such preparatory work is essential to ensure the 
proper conduct of scientific studies, but the significant human, logistic, and financial resources 
required are usually not considered sufficiently beforehand by both scientists and funding 
organizations [29]. In Indonesia, the complete laboratory infrastructure had to be set up in a 
remote area of an island where the study center was located, which required several weeks of 
construction work. A short video showing the different study procedures as well as the 
laboratory infrastructure before and after the onset of the NIDIAG study in Maluku Tengah can 
be found in the Supplementary Material of this manuscript (S34). Of note, even minor logistic 
issues may have a profound impact. In Côte d’Ivoire and Nepal, for example, the absence of a 
functioning ventilation and climate control system in the laboratories led to several short delays 
in recruitment and specimen processing, as stool samples are unpleasant to work with and the 
study was thus not initiated before the ventilation systems were fixed. 
Study site investigators frequently reported that the volume of a single stool sample was 
smaller than the amount stipulated in the respective SOP, and was thus not sufficient to perform 
all required laboratory tests. Indeed, an amount of approximate 80 g of stool was required to run 
all tests (Table 2), as several diagnostic techniques such as the Baermann funnel concentration 
for the diagnosis of Strongyloides stercoralis require a large amount of stool. In such cases, a 
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second sample had to be obtained from participants, but especially children were not always able 
to provide the required amount and sometimes did not come back to provide the requested 
second sample. 
Due to the host of different laboratory tests, the processing of a sample took approximately 2 
to 3 hours, and it would have been ideal to collect stool specimens in the early morning and 
analyze them immediately in the laboratory. However, this was not always possible as the sites 
of patient enrolment were sometimes quite distant from the actual laboratory (e.g., the Dhankuta 
study site in Nepal) or the study laboratories had to send parts of the sample to reference 
laboratories (e.g., in Côte d’Ivoire and Mali, for stool bacteriology in case of persistent diarrhea). 
Such sample transfer had to be organized and carried out by couriers, so that laboratory staff 
sometimes worked until late in the evening when a sample arrived only in the afternoon. 
With regard to difficulties associated with specific laboratory techniques, few deviations 
were observed and the study investigators complied very well with the various SOPs. This 
observation was largely attributed to the two in-depth preparatory workshops that had taken 
place prior to the start of the study. Some of the remaining challenges experienced and potential 
solutions to overcome these are presented in Table 3. 
 
  
Table 3. Diagnostic challenges encountered during the NIDIAG study on persistent digestive disorders, and proposed 
solutions. 
Diagnostic test Problem Possible reason Solution 
Rapid diagnostic 
test (RDT) for 
Cryptosporidium 
and 
G. intestinalis 
Faintly positive test line that 
is hard to interpret as either 
positive or negative test 
result 
An inaccurate volume of stool 
sample may have been used 
While an exact amount of liquid stool 
samples could easily be taken via 
pipettes, this was less standardized for 
solid samples. All positive or faintly 
positive RDT results were 
documented by photography and 
results will be compared to subsequent 
microscopic and molecular diagnostics 
RDT for 
Cryptosporidium 
and 
G. intestinalis 
During internal quality 
control, a Cryptosporidium-
positive stool sample led to 
inconsistent results upon 
RDT application 
False-negative results were 
exclusively observed on expired or 
nearly expired RDTs 
Strict adherence to the indicated 
expiration dates of RDTs in clinical 
studies and routine diagnostics 
Formalin-ether 
concentration 
Difficult microscopic 
reading of stool samples 
following formalin-ether 
concentration 
Questionable quality of the locally 
obtained ether 
Identify alternative provider for ether 
and other chemical products required 
for analysis (proved to be difficult in 
some study countries) 
Mini-FLOTAC Leakage of one flotation 
chamber 
The utilized Mini-FLOTAC 
apparatus can be re-used after 
disinfection. However, the washing 
procedure may influence the 
stability of the flotation chambers 
Apply vaseline on the septum/partition 
of the Mini-FLOTAC to prevent 
leakage 
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Conclusions 
As the NIDIAG project draws to an end, we feel that experiences and lessons learnt must be 
shared with the broader research community, clinicians, and disease control managers in 
countries where digestive disorders due to NTDs remain an important public health issue 
(Box 1). The current set of field-tested and ready-to-use SOPs has been implemented 
successfully in various sites, including those located in areas with restricted resources. We 
hope that providing open-access to this large compilation of SOPs and highlighting key 
challenges met during the implementation and the conduct of the NIDIAG study on persistent 
digestive disorders might assist in further training and capacity building on all aspects of 
patient recruitment, clinical and diagnostic work-up, within GCP/GLCP standards, data 
management, and quality control, and thus improve the clinical-diagnostic algorithms for 
patients suffering from NTDs. We look forward to experiences and lessons by other groups 
pursuing syndromic approaches to advance the diagnosis and clinical management of NTDs 
among neglected populations. 
 
Box 1. Key Learning Points from the Multi-Country NIDIAG Study on Persistent 
Digestive Disorders in the Tropics 
 There is a need for studies investigating the etiology, diagnosis, and management of 
common clinical syndromes such as persistent digestive disorders in the tropics. 
Easily applicable, evidence-based diagnosis-treatment algorithms could substantially 
improve the clinical management of such syndromes at the primary health care level. 
 The implementation of a quality assurance system is crucial for the conduct of 
multicentric clinical studies in resource-restricted settings, and it remains an 
ambitious goal to perform studies that fully comply with good clinical practice (GCP) 
and good clinical laboratory practice (GCLP). 
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 Study documents such as standard operating procedures (SOPs) and case report forms 
(CRFs) should be jointly developed and validated to harmonize procedures across 
study sites. Such field-tested tools are an important resource for researchers and 
health care staff, and should thus be made publicly available. 
 In a study on persistent digestive disorders, which was carried out by the Neglected 
Infectious Diseases Diagnostics (NIDIAG) consortium, perceived challenges were the 
prolonged recall period (≥14 days) for the identification of individuals with persistent 
abdominal pain and persistent diarrhea, and the considerable heterogeneity seen 
regarding the recruitment pace of patients and controls in the four study countries. 
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Supporting Information Legends 
S1 Clinical SOP. History taking. 
S2 Clinical SOP. Clinical examination. 
S3 Clinical SOP. Selection of controls without digestive syndrome. 
S4 Clinical SOP. Specific treatment procedures (including dosage). 
S5 Clinical SOP. Assessing inclusion and exclusion criteria. 
S6 Clinical SOP. Patient recruitment and patient flow. 
S7 Laboratory SOP. Kinyoun staining technique (used in Côte d’Ivoire, Mali, and Nepal). 
S8 Laboratory SOP. Modified acid-fast staining technique (used in Indonesia). 
S9 Laboratory SOP. Crypto-Giardia Duo-Strip rapid diagnostic test (RDT). 
S10 Laboratory SOP. Kato-Katz technique. 
S11. Laboratory SOP. Baermann technique. 
S12 Laboratory SOP. Mini-FLOTAC technique. 
S13 Laboratory SOP. How to obtain a stool sample. 
S14 Laboratory SOP. Formalin-ether concentration technique. 
S15 Laboratory SOP. Koga agar plate culture. 
S16 Laboratory SOP. Direct fecal smear technique. 
S17 Laboratory SOP. Preparation of aliquots for molecular post-hoc testing. 
S18 Laboratory SOP. Urine point-of-care circulating cathodic antigen (POC-CCA) RDT for 
the diagnosis of Schistosoma mansoni. 
S19 Laboratory SOP. Diagnostic sample flow. 
S20 Laboratory SOP. Urine sampling. 
S21 Quality SOP. Obtaining informed consent. 
S22 Quality SOP. Numbering system to be used in NIDIAG studies. 
S23 Quality SOP. Management of study documents. 
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S24 Quality SOP. SOP on SOPs. 
S25 Quality SOP. External monitoring. 
S26 Quality SOP. Internal quality control activities. 
S27 Quality SOP. Good clinical laboratory practice (GCLP) supervision visits. 
S28 Quality SOP. Min/max thermometer. 
S29 Quality SOP. Stock management. 
S30 Quality SOP. Handling of expired and disqualified products. 
S31 Quality SOP. Handling and storage of rapid diagnostic tests (RDTs). 
S32 Data management SOP. Completing case report forms (CRFs). 
S33 Data management SOP. Procedure for data management. 
S34 Video. The NIDIAG study site in Maluku Tengah, Indonesia. 
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10  Discussion 
10.1 Summary of research objectives and key findings 
The current Ph.D. thesis was embedded in the multi-country, EC-funded NIDIAG study 
(NIDIAG is the acronym for ‘Better DIAGnosis of Neglected Infectious diseases; see 
http://www.nidiag.org). The overarching goal of the thesis was to elucidate the aetiology of 
persistent digestive disorders in resource-constrained tropical settings, to evaluate new 
diagnostic approaches and to contribute to the development of novel, evidence-based clinical 
algorithms that may be employed for the management of persistent digestive disorders at the 
peripheral healthcare level. While diarrhoeal diseases are among the most important 
infectious causes of disease worldwide (second only to lower respiratory infections), prior 
research mainly focussed on acute diarrhoea or single pathogens rather than considering 
persistent digestive disorders as a distinct clinical syndrome. Hence, the main specific 
objectives of the current thesis were (i) to review the set of pathogens that may cause 
persistent diarrhoea (≥14 days; in all age groups) and persistent abdominal pain (≥14 days; in 
individuals aged 1-18 years) in tropical and subtropical countries; (ii) to develop a study 
protocol for a prospective, multi-country investigation pertaining to this clinical syndrome; 
and (iii) to assess the aetiology of persistent digestive disorders by the application and 
diagnostic comparison of conventional stool microscopy, RDTs and multiplex PCR. 
 
The research mission of the Swiss Tropical and Public Health Institute (Swiss TPH) is based 
on three major pillars, all of which are equally important to advance science: innovation, 
validation and application. The various studies carried out during the current Ph.D. thesis 
have contributed in several ways to this value chain. Table 10.1 summarises the main 
findings and contributions of this Ph.D. thesis within the nexus of innovation, validation and 
application. In brief, the systematic review elucidated that more than 40 bacterial, parasitic 
(helminths and intestinal protozoa) and viral pathogens may cause persistent abdominal pain 
and/or persistent diarrhoea. The subsequently performed case-control study in Dabou, south 
Côte d’Ivoire identified a considerable setting-specificity and a high number of asymptomatic 
intestinal infections in healthy controls, which were taken into account for the development 
of the NIDIAG study protocol for a multicentric investigation pertaining to persistent 
digestive disorders. While the application of some innovative molecular diagnostics (e.g. 
multiplex PCR) in Côte d’Ivoire elucidated the insufficient diagnostic accuracy of 
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conventional diagnostic methods, the unexpected detection of many pathogens even in 
asymptomatic controls calls for an urgent revision of previously well-established concepts 
regarding the aetiology and pathogenesis of infectious diseases. Importantly, the diagnostic 
accuracy of available RDTs for the detection of C. difficile, Cryptosporidium spp., 
G. intestinalis and S. mansoni was assessed to define their potential suitability to be used for 
clinical decision-making at the peripheral healthcare level where sophisticated laboratory 
facilities are often not available. 
 
While the specific technical limitations of the research studies carried out during this Ph.D. 
thesis have been presented in detail in the respective chapters, four implications of the current 
work shall here be discussed in a broader context and in further detail: (i) the burden and 
local epidemiology of persistent digestive disorders; (ii) implications of rapid diagnostic tests 
for epidemiological studies and individual patient management; (iii) concepts in transition: 
the complex pathogenesis of intestinal infections; and (iv) novel approaches for a syndromic 
management of digestive disorders. 
 
  
 
Table 10.1 Overview of the major findings and contributions of the respective chapters in the current Ph.D. thesis, stratified by the three main 
research pillars at the Swiss TPH, namely innovation, validation and application. 
Chapter Title Innovation Validation Application 
3 Persistent digestive disorders in the tropics: 
causative infectious pathogens and 
reference diagnostic tests 
   
Explanation: First systematic review specifically targeting pathogens that may cause 
persistent diarrhoea, persistent abdominal pain and blood in the stool, with a particular 
focus on reference tests and diagnostic tools that could be utilised in resource-
constrained tropical settings. 
4 Diagnosis of neglected tropical diseases 
among patients with persistent digestive 
disorders (diarrhoea and/or abdominal pain 
≥14 days): a multi-country, prospective, 
non-experimental case-control study 
   
Explanation: Detailed protocol of a multicentre study to elucidate the aetiology, 
clinical features, diagnosis and existing management algorithms for persistent digestive 
disorders in Africa (Côte d’Ivoire and Mali) and Asia (Indonesia and Nepal). 
5 Experiences and lessons from a multi-
country NIDIAG study on persistent 
digestive disorders in the tropics 
   
Explanation: Complete set of 33 SOPs for the NIDIAG digestive study that give 
detailed information on the application of clinical, laboratory, quality control and data 
management activities. 
6 Combined stool-based multiplex PCR and 
microscopy for enhanced pathogen 
detection in patients with persistent 
diarrhoea and asymptomatic controls from 
Côte d’Ivoire 
   
Explanation: The first case-control study in south Côte d’Ivoire that employed a 
combination of multiplex PCR, rapid diagnostic tests, conventional microscopic 
methods and clinical features to assess bacterial, parasitic and viral pathogens and their 
association with persistent diarrhoea. 
  
 
 
Chapter Title Innovation Validation Application 
7 Real-time PCR for detection of 
S. stercoralis in human stool samples 
from Côte d’Ivoire: diagnostic accuracy, 
inter-laboratory comparison and patterns 
of hookworm co-infection 
   
Explanation: Rigorous diagnostic comparison of two microscopic techniques and real-
time PCR methods (independently employed in two laboratories) for detection of 
S. stercoralis in human stool samples, including a word of caution pertaining to 
misidentification of hookworm larvae as S. stercoralis in diagnostic laboratories. 
8 Molecular and culture-based diagnosis of 
C. difficile isolates from Côte d’Ivoire 
after prolonged storage at disrupted cold 
chain conditions 
   
Explanation: Presentation of the feasibility and diagnostic accuracy of a two-step 
algorithm to investigate C. difficile in West Africa, consisting of an RDT screening on 
site and subsequent transfer of RDT-positive samples to a specialised laboratory for in-
depth investigations (stool culture and PCR). 
9 Application in Europe of a urine-based 
rapid diagnostic test for confirmation of 
S. mansoni infection in migrants from 
endemic areas 
   
Explanation: First-ever application of a diagnostic tool (POC-CCA urine cassette test), 
which has previously been validated in epidemiological studies in endemic settings, for 
individual patient diagnosis of individuals with suspected schistosomiasis in Europe 
(‘reverse innovation’). 
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10.2 The burden and local epidemiology of persistent digestive disorders 
Persistent diarrhoea and persistent abdominal pain are important causes of morbidity and 
mortality worldwide, particularly in areas of poor sanitation and weak health systems [1,2]. 
While acute diarrhoea is a commonly recognised cause of child mortality, it has recently been 
shown that persistent diarrhoea accounted for 56.3%, 44.9% and 12.2% of diarrhoea-
associated deaths in children aged between 1 and 4 years in Ethiopia, Uganda and the United 
Republic of Tanzania, respectively [3]. Persistent diarrhoea may cause severe sequelae such 
as malabsorption, pancreatic and gastric dysfunction and specific nutritional deficiencies [4-
6]. Indeed, an Ethiopian study reported that persistent diarrhoea constituted only 5% of all 
diarrhoea cases in children that were seen at a referral hospital in Addis Ababa, but 86% of 
these patients had signs of accompanying malnutrition [7]. According to recent data 
stemming from the Taabo health and demographic surveillance system (HDSS) in south-
central Côte d’Ivoire, diarrhoeal diseases account for 5.5% of all deaths in children aged 
below 5 years [8,9]. The importance of persistent digestive disorders in resource-constrained 
settings has been confirmed during the ongoing NIDIAG study. During the first study 
performed in Dabou (chapter 6 of this Ph.D. thesis), 68 patients with persistent diarrhoea 
could be enrolled within 3 weeks [10]. At the time of writing, the patient recruitment for the 
multi-country NIDIAG digestive study has just been completed, and the obtained results 
further underscore the frequency of persistent digestive disorders. Indeed, 553 patients with 
persistent digestive disorders and 553 asymptomatic controls have been recruited at the 
NIDIAG study site in Niono, Mali during an enrolment period of less than 10 months. 
 
As shown in this Ph.D. thesis (chapter 3), persistent digestive disorders may be caused by 
more than 40 infectious agents, but there is also considerable setting-specificity with regard 
to the predominant pathogens. During our NIDIAG site assessment study in Dabou, Côte 
d’Ivoire, only four pathogenic agents were identified in ≥10% of all symptomatic patients, 
namely enterotoxigenic E. coli (ETEC; 34% prevalence), G. intestinalis (27%), Shigella spp. 
(27%) and S. stercoralis (12%). These results confirm previous studies in Côte d’Ivoire that 
reported S. stercoralis to be endemic in rural areas, with prevalences as high as 48% in some 
villages [11]. Additionally, a study employing morbidity questionnaires and a standardised 
medical examination showed that both S. stercoralis and hookworm are significantly 
associated with gastrointestinal symptoms (e.g. abdominal pain and diarrhoea) in rural Côte 
d’Ivoire [12]. Unfortunately, the correct diagnosis of S. stercoralis is cumbersome and a 
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combination of laborious microscopic methods and PCR should be employed to achieve the 
highest diagnostic accuracy. Due to the unavailability of these techniques in many resource-
constrained settings, it is conceivable that a considerable number of S. stercoralis infections 
are missed. Hence, the development of a sensitive RDT for this pathogen is warranted. 
 
G. intestinalis, the second commonly detected intestinal parasite in patients with persistent 
diarrhoea in Dabou, was known to be endemic in Côte d’Ivoire, as it had been studied mainly 
in the context of polyparasitism with multiple helminthic and other intestinal protozoon 
infections [13-16]. Indeed, self-reported morbidity could be linked to such intestinal 
polyparasitism [17] and intestinal parasitic infections reduced the self-rated quality of life of 
infected individuals significantly [18]. Furthermore, there is a clear link between poor 
sanitation, lack of hygiene, defecation behaviour, unsafe sources of drinking water and higher 
prevalences of soil-transmitted helminths and intestinal protozoa, thus underscoring the close 
connection between these NTDs and poverty [19,20]. Asymptomatic carriage of 
G. intestinalis is a common feature in low-income countries, which renders the attribution of 
clinical symptoms to the finding of this protozoon in the stool difficult. However, a 
systematic review and meta-analysis have elucidated a significant association between 
G. intestinalis and persistent diarrhoea (adjusted odds ratio 3.18, p<0.001), while this was not 
observed for acute diarrhoeal episodes and G. intestinalis infection [21].  
 
In contrast to intestinal parasites, only little emphasis has been placed on bacterial and viral 
pathogens in the context of gastrointestinal disorders in resource-limited countries, which 
may partially be explained by the lack of well-equipped diagnostic laboratories in these 
settings [22]. However, considerable efforts have been made in recent years to capture the 
whole aetiological spectrum of acute diarrhoea, including bacterial and viral pathogens, in 
low-income countries. Most noteworthy is the Global Enteric Multicenter Study (GEMS), an 
international research consortium that performed a 3-year prospective case-control study in 
seven sites in sub-Saharan Africa and southern Asia to gain insights on the prevailing 
pathogens in children aged below 5 years with acute moderate-to-severe diarrhoea [23]. 
Similar to our findings from Côte d’Ivoire, at least one pathogen was identified in 83% of 
cases and 72% of controls. Despite the large number of pathogens being investigated, only 
four infectious agents were significantly associated with moderate-to-severe diarrhoea in all 
sites, namely rotavirus, Shigella spp., ETEC and Cryptosporidium spp. [24]. Likewise, 
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Shigella spp. and ETEC constituted also the most prevalent pathogens in our study in Dabou 
and it will be interesting to see whether similar results will be obtained when analysing the 
data from the currently ongoing, multi-country NIDIAG study that is carried out in Côte 
d’Ivoire, Indonesia, Mali and Nepal. Indeed, the importance of Shigella spp. as diarrhoea-
causing agent has also been acknowledged by a case-control study from Ecuador [25]. A 
recent study in the People’s Republic of China assessed differences between the urban area of 
Beijing and a rural area in the Henan province, an area of poor sanitation and hygiene. 
Strikingly, Shigella spp. was by far the predominant bacterial pathogen in the rural area and 
its prevalence was more than 30-fold higher than in Beijing [26]. Hence, the currently 
ongoing development of a vaccine against shigellosis is of crucial importance, as it might 
have a significant beneficial impact on child health in low-income countries [27], similar to 
what has been observed after the introduction of the rotavirus vaccine [28,29]. Yet, the 
considerable setting-specificity of digestive disorders and the varying range of causative 
pathogens in many settings may limit the suitability of approaches targeting single pathogens 
to decrease the disease burden in communities [30], and interventions promoting improved 
access to safe water, sanitation and hygiene (WASH) should concurrently be encouraged [31-
33]. 
 
Several barriers exist that hinder research on persistent digestive disorders in resource-
constrained settings. First, the multi-faceted aetiology of these infections requires a battery of 
microbiological laboratory investigations to be carried out, which is logistically challenging 
and often impossible in tropical countries. Second, there is no objective standard definition 
for the entity ‘persistent abdominal pain’, which may influence on the comparability of 
different studies [34]. Third, the health-seeking behaviour of patients suffering from 
persistent digestive disorders also needs to be considered. Indeed, researchers from Yemen 
performed a qualitative study to assess local concepts of illness and found that diarrhoeal 
diseases were usually not judged by the local population as illnesses that would require 
medical treatment [35]. Hence, traditional medicine was much more frequently used to treat 
these conditions, and physicians were rarely consulted. A similar study conducted in 
Bamako, Mali assessed the health-seeking behaviour for paediatric diarrhoea and found that 
the more severe diarrhoea cases were more likely to present to traditional healers than to 
trained health professionals at governmental healthcare centres [36]. It follows that the 
burden of diarrhoeal and other digestive diseases may be underestimated if only patients 
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presenting to major health centres or hospitals are considered. Similar experiences have been 
made during the NIDIAG digestive study in Côte d’Ivoire and Mali and it will thus be 
interesting to analyse the results of the NIDIAG study also in light of the patients’ health-
seeking behaviour, so that clinical management algorithms can subsequently be implemented 
in those settings where most patient with persistent diarrhoea and abdominal pain present.  
 
10.3 Implications of RDTs for epidemiological studies and individual 
patient management 
In the different chapters of the current Ph.D. thesis, various diagnostic tools have been 
utilised that can be grouped into three major categories: (i) conventional microscopic tests 
that allow for direct visualisation of a pathogen; (ii) pathogen-specific RDTs, which use dye-
labelled antibodies to detect antigen of a target pathogen; and (iii) nucleic acid amplification 
tests that directly detect genetic material (DNA or RNA) of a specific pathogen via PCR. 
RDTs and PCR assays targeting NTDs and other major pathogens in tropical settings have 
been developed relatively recently. While PCR and microscopy require a rather well-
equipped diagnostic laboratory, RDTs can be performed even under harsh field conditions, 
such as in peripheral, underequipped healthcare centres in rural sub-Saharan Africa [37]. The 
most prominent example for a widespread implementation of RDTs in resource-limited areas 
is malaria, an infection caused by blood parasites of the genus Plasmodium [38]. The 
implementation of these tests allowed for malaria testing in many rural health centres without 
laboratory facilities, where case management previously relied exclusively on clinical 
judgment [39]. In 2010, WHO recommended that all patients with suspected malaria should 
undergo testing for malaria (instead of starting presumptive treatment), using RDTs in most 
areas where light microscopy was not available. However, strategies that rely exclusively on 
treating RDT-positive patients for malaria have been repeatedly criticised for a number of 
reasons [40], e.g. the possibility of other causative diseases despite a positive malaria RDT in 
highly endemic settings [41], false-negative results due to the prozone effect [42] and cost-
effectiveness concerns [43]. 
 
RDTs have also been developed for intestinal pathogens and have found their way into daily 
clinical practice in many laboratories in Europe and North America. The most commonly 
used tests are those targeting the three intestinal protozoa species Cryptosporidium spp., 
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E. histolytica and G. intestinalis [1]. However, it is important to note that there is no 
commercially available RDT that can reliably distinguish E. histolytica from the apathogenic, 
yet morphologically identical E. dispar [44]. For G. intestinalis, the sensitivity of RDTs has 
been reported to be superior to that of microscopy in samples stemming from patients with 
acute diarrhoea. In the current Ph.D. thesis, an RDT for G. intestinalis detection 
(Crypto/Giardia DuoStrip; Coris BioConcept, Gembloux, Belgium) has been applied in Côte 
d’Ivoire for persistent diarrhoea, but the results were disappointing. Indeed, the sensitivity of 
the RDT in comparison to PCR and microscopy was only 40% [10]. This might partially be 
explained by a relatively low quantity of Giardia cysts being shed in the faeces of patients 
with persistent diarrhoea, because the sensitivity of stool microscopy was also unexpectedly 
low (51%). However, a recent diagnostic comparison study from Belgium confirmed the 
insufficient diagnostic accuracy of the RDT employed here (Crypto/Giardia DuoStrip), with a 
reported sensitivity for G. intestinalis detection of only 58-66% [45]. 
 
RDTs for Cryptosporidium detection are particularly useful, because the small oocysts of 
these coccidian parasites are easily missed upon stool microscopy (e.g. when a formalin-ether 
concentration technique is employed) and are only visible when staining techniques (e.g. 
acid-fast staining) are utilised. Hence, it is conceivable that infections due to 
Cryptosporidium spp. are underreported worldwide, despite the growing evidence concerning 
the substantial contribution of cryptosporidiosis to the burden of diarrhoeal diseases, which 
has recently been confirmed in the GEMS study [24]. In contrast to previous concepts, it is 
now widely acknowledged that cryptosporidiosis is not limited to HIV-infected individuals 
[46-48]. Hence, a wider application of diagnostic tests targeting Cryptosporidium spp. in 
resource-limited settings is recommended. Besides RDTs for intestinal protozoa, it would 
also be useful to enhance the availability of bacterial RDTs for detection of the C. difficile-
specific GDH in tropical areas. This RDT is a highly sensitive, validated tool that can be used 
as a reliable screening test for C. difficile-associated infections, e.g. in patients who develop 
diarrhoea while receiving antibiotic treatment. While C. difficile is estimated to account for 
more than 95% of all diarrhoea-associated deaths in elderly people in the Western world [49], 
its epidemiology and medical importance in Africa are poorly understood. Preliminary 
findings from this Ph.D. thesis point towards significant differences regarding the 
predominating C. difficile strains in sub-Saharan Africa. Hence, hospital-based and 
epidemiological studies investigating the causes of diarrhoeal diseases in the tropics should 
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consider screening for C. difficile using an RDT; positive samples could then be sent to a 
reference laboratory for further diagnostic work-up. 
 
In contrast to the aforementioned protozoal and bacterial RDTs, the POC-CCA urine cassette 
test for diagnosis of S. mansoni is the only validated and commercially available RDT for 
helminths. Its diagnostic accuracy and superior sensitivity compared to stool microscopy 
have been shown in multi-country studies [50-52], even though recent research has 
questioned whether there may be a certain level of false-positive test results in pregnant 
women [53]. In chapter 9 of this Ph.D. thesis, it has been shown that the POC-CCA test can 
also be utilised for the confirmation of suspected intestinal schistosomiasis in migrants from 
endemic areas or returning travellers [54]. Surprisingly, such a broader implementation of the 
POC-CCA test has not yet occurred in travel clinics and hospitals. However, by the time of 
writing the current work, we have identified a total of six RDT-positive cases in migrants 
from Eritrea in the Institute of Medical Microbiology and Hygiene (IMMH) in 
Homburg/Saar, Germany, out of which some patients would not have been detected by stool 
microscopy. In addition to the high sensitivity, this non-invasive RDT may also considerably 
reduce the costs for unnecessary diagnostic investigations in patients with schistosomiasis-
associated morbidity (e.g. colonoscopy in patients with persistent abdominal pain). Hence, a 
wider application of the POC-CCA test for the clinical management of patients from endemic 
areas should be encouraged in Europe and elsewhere, because an early detection and 
subsequent treatment of intestinal schistosomiasis might avert considerable morbidity in 
infected individuals. 
 
10.4 Concepts in transition: the complex pathogenesis of intestinal 
infections  
PCR-based techniques are characterised by high diagnostic sensitivity, which has been 
confirmed in the current work [10,55], even though the diagnostic accuracy of PCR assays 
for some parasitic pathogens (e.g. S. stercoralis) is at present not high enough to replace 
conventional microscopic methods [56]. However, in the current work, the application of 
PCR techniques on stool samples also detected high rates of intestinal pathogens in 
asymptomatic individuals. Surprisingly, for most bacterial, parasitic and viral pathogens, no 
significant prevalence differences among patients and controls could be identified. In 
agreement with these findings, recent studies employing multiplex PCR on stool samples of 
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asymptomatic individuals confirmed this observation [57]. Apparently, this phenomenon is 
not limited to the gastrointestinal tract, because similar results have also been reported from 
studies that employed PCR-based techniques to investigate patient blood samples for 
pathogens giving rise to systemic infections. Indeed, a study from Gabon identified common 
bacterial pathogens such as S. aureus and fastidious bacteria such as Borrelia spp. and 
Rickettsia felis in a certain amount of afebrile children [58]. It has thus recently been 
suggested to include, whenever possible, asymptomatic controls in epidemiological studies to 
improve our understanding regarding the aetiology of infections and the role of detected 
pathogens [59,60]. 
 
In the case of diarrhoeal diseases and digestive disorders, several considerations might help to 
explain the finding of considerable pathogen prevalences in healthy controls. First, 
asymptomatic colonisation with infectious agents may occur and could be explained by (i) 
the recent ingestion of very small amounts of the pathogen, which are not sufficient to cause 
human disease; (ii) the ingestion of animal pathogens that cannot cause human disease, but 
cannot reliably be differentiated by PCR (e.g. porcine ETEC pathotypes); and (iii) the fact 
that PCR detects nucleic acids stemming from a pathogen, but cannot distinguish between 
live and dead organisms, meaning that PCR-positive signals due to prolonged nucleic acid 
shedding may persist for weeks or months after a resolved infection [61]. Additionally, 
bacteria such as ETEC just cause disease when they are located in the small intestine, while 
apathogenic colonisation in the large intestine may occur [62]. For some pathogens (e.g. 
Blastocystis spp., Campylobacter spp., G. intestinalis), there is growing evidence that only 
some strains, which can only be differentiated by detailed molecular analysis, may cause 
disease [61]. ‘Environmental contamination’ with small amounts of potentially disease-
causing pathogens as well as dietary habits and the composition of the intestinal flora may 
also play a decisive role whether nucleic acids of a pathogen can be detected by PCR. In 
summary, while the sensitivity of conventional diagnostic techniques is frequently too low to 
detect all clinically meaningful infections, PCR techniques are characterised by a very high 
analytical sensitivity, which may in turn ‘overdiagnose’ pathogens due to detection of 
irrelevant quantities of nucleic acids. Hence, there is a need to define the characteristics of an 
optimal diagnostic assay and to establish ‘clinical thresholds’ for PCR-based testing 
methodologies (Figure 10.1). 
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In a recent proof-of-concept study, we have shown that a metagenomics approach, i.e. the 
application of molecular sequencing techniques to characterise whole microbial communities 
without isolating or culturing the individual pathogens, may provide additional information 
on the intestinal microbiome [63]. Four stool samples stemming from our study on persistent 
diarrhoea in Dabou were purposefully selected and subjected to a metagenomics approach. 
Strikingly, up to 11 pathogen classes could be identified in a single stool specimen, which 
sheds further doubt on the established concept that the presence or absence of one single 
causative agent may determine the onset of infectious pathologies of the intestinal tract. 
Hence, it is conceivable that the whole composition of the gut microbiome, i.e. the entire 
intestinal flora, as well as its interactions with the human host influence whether or not an 
individual develops overt disease [64,65]. Future research in high-income and low-income 
countries is needed to further our understanding of these complex interactions and to develop 
innovative concepts pertaining to the pathogenesis of intestinal infections. 
 
 
Figure 10.1 Detection limit of different diagnostic assays in relation to a ‘clinical threshold’ 
(published in [66]). 
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10.5 Novel approaches for a syndromic management of digestive 
disorders 
One of the main objectives of the ongoing NIDIAG study is the development of novel, 
evidence-based clinical algorithms that enable an improved diagnosis and management of 
individuals presenting with persistent digestive disorders (≥14 days) at the peripheral 
healthcare level. Based on the findings reported in this Ph.D. thesis, several lessons can be 
learned, which will be further influenced by the final study results of the NIDIAG study. 
Indeed, at the time of writing, the enrolment of patients and controls has successfully been 
completed in all four study countries (Côte d’Ivoire, Indonesia, Mali and Nepal) and an 
‘algorithm development workshop’ has been held in Bamako in mid-November 2015. Study 
findings from Nepal are currently being entered into an electronic database and have not yet 
been analysed, while the number of patients with persistent digestive disorders encountered 
in Indonesia was very low, so that the original study design had to be adapted. Hence, the 
following considerations will mainly address NIDIAG data from Côte d’Ivoire and Mali as 
well as the results from the studies that were performed as part of this Ph.D. thesis. 
 
There is a clear need for the development of setting-specific algorithms, as the major 
aetiological agents causing persistent digestive disorders as well as the associated signs and 
symptoms may vary considerably in different regions. With regard to the clinical 
symptomatology, significant differences were observed during the NIDIAG study. Indeed, 
more than 90% of all enrolled patients in Mali complained about persistent abdominal pain, 
whereas persistent diarrhoea was more frequently reported in Côte d’Ivoire. While 
S. stercoralis is one of the most important helminths contributing to this syndrome in Côte 
d’Ivoire [10,56], there have been hardly any cases of strongyloidiasis during the NIDIAG 
study in neighbouring Mali, where schistosomiasis (both due to S. mansoni and 
S. haematobium) seems to play a major role in the pathogenesis of persistent abdominal pain 
in children and adolescents. Giardiasis is highly prevalent across both countries and the 
systematic follow-up of patients during the NIDIAG study revealed a substantial clinical 
improvement or complete resolution of symptoms after treatment with metronidazole in 
patients infected with G. intestinalis. The role of bacteria as contributors to persistent 
digestive disorders remains unclear. The multiple positive PCR signals obtained in both 
patients and controls render an attribution of morbidity to the different pathogens very 
difficult. Additionally, most patients with confirmed parasitic diseases and positive PCR 
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signals for bacterial pathogens improved on antiparasitic treatment alone (i.e. albendazole, 
ivermectin, praziquantel or metronidazole). Hence, it seems to be justified to focus mainly on 
helminthic and protozoal agents in the context of persistent digestive symptomatologies that 
occur in tropical settings. 
 
The novel diagnosis-treatment algorithms shall be utilised in primary healthcare centres, 
where few adjunctive diagnostic tools besides clinical judgment are available. Hence, RDTs 
would constitute the only available diagnostic tests. Indeed, two RDTs seem to be 
particularly useful for the management of persistent digestive disorders and the decision 
whether to initiate targeted treatment, i.e. the POC-CCA urine cassette test for S. mansoni (an 
important pathogen in the NIDIAG setting in Mali) and an RDT for G. intestinalis (high 
prevalences in both Côte d’Ivoire and Mali). However, the overall prevalence of a given 
infection in symptomatic patients is also important to decide whether diagnostic testing 
should at all be implemented; if the prevalence of a specific pathogen in a given area is very 
high, the clinical signs and symptoms alone may be sufficient to initiate presumptive 
treatment. The ‘decision threshold’ when to start such an empirical medical treatment greatly 
depends on (i) the potential toxicity of the drug; and (ii) the potential long-term morbidity 
caused by an untreated infection. With regard to schistosomiasis, for example, treatment with 
praziquantel has few adverse events, is efficacious and potentially prevents long-term 
morbidity such as hepatic fibrosis and subsequent portal hypertension [67,68]. Hence, the 
‘decision threshold’ is conceivably relatively low in the context of persistent digestive 
disorders. The application of RDTs could also be important to decide whom not to treat with 
anti-infective drugs. Due to the high number of observed co-infections with S. mansoni and 
G. intestinalis in the digestive syndrome study site in Mali, the application of an RDT for e.g. 
G. intestinalis may help to decide whether an anti-protozoal and an anthelminthic drug should 
be administered concurrently or whether there is no need for anti-protozoal treatment. 
 
The clinical features of digestive infections are usually unspecific, and hence, do not allow to 
distinguish between specific pathogens. However, diarrhoea and nausea have been repeatedly 
linked to strongyloidiasis and hookworm disease in Côte d’Ivoire, and intestinal helminth 
infections in general may also cause extraintestinal disease manifestations such as wheezing 
on pulmonary auscultation and cutaneous manifestations (e.g. itching and rash) [69]. After 
having analysed the entire NIDIAG dataset from the study countries, it will be interesting to 
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see whether a clear link between intestinal helminthiasis and such suggestive clinical findings 
can be elucidated, which would be very valuable for subsequent clinical algorithms. The final 
NIDIAG algorithm for the management of persistent digestive disorders will most likely be 
relatively simple and will consist of a clinical assessment to establish whether the definition 
of persistent digestive disorders is met, followed by either a presumptive treatment with one 
or two drugs that would cover the most important pathogens (particularly in areas where a 
limited number of pathogens are highly prevalent), or by application of one or two RDTs to 
determine the potential cause of the disorders (e.g. to rule out intestinal schistosomiasis in 
settings of low endemicity). A clinical improvement should normally be seen within one 
week after starting medical treatment; hence, persisting symptomatologies would require 
referral to the next healthcare level; thus a district or reference hospital. However, based on a 
preliminary analysis of findings from the NIDIAG study, it seems that such a referral will be 
required for less than 5% of all patients. 
 
Insights gained from previous studies pertaining to the implementation of clinical algorithms 
in resource-limited settings revealed a clear need to critically validate and evaluate these 
algorithms in collaboration with the local caregivers, e.g. for the diagnosis and management 
of dengue fever [70], human African trypanosomiasis [71], malaria [72] and pulmonary 
tuberculosis [73]. Indeed, the NIDIAG algorithms will only be utilised if they prove to be 
valid and helpful under ‘real life conditions’. An integrated management of common clinical 
syndromes has the potential to improve the clinical care of symptomatic patients and to 
concurrently decrease the irrational use of anti-infective drugs [74]. Hence, the first NIDIAG 
algorithm for an evidence-based management of persistent digestive disorders will be 
developed after complete data analysis and will then be validated in a subsequent study in 
Niono, Mali in early 2016. Eventually, the algorithm might be implemented at multiple 
primary healthcare centres in this area to provide evidence-based guidance for an improved 
clinical management of persistent diarrhoeal and digestive diseases. 
 
10.6 Recommendations and research needs 
The current work assessed persistent diarrhoea and persistent abdominal pain to investigate 
the significance of these symptomatologies in resource-limited settings of the tropics, to 
elucidate the potentially implicated pathogens and to compare several clinical and laboratory 
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diagnostic features. Several suggestions and research needs arise from the results obtained in 
the present work: 
 
1. Persistent digestive disorders are of considerable importance in resource-limited settings, 
but a particular health-seeking behaviour needs to be considered. If compared to acute 
and more rapidly progressing diseases, minor attention is directed towards persistent 
digestive disorders and hence, patients rarely present to hospitals or large health centres. 
Therefore, future studies investigating this clinical syndrome should closely collaborate 
with peripheral healthcare centres in rural areas. There is considerable setting-specificity 
and persistent digestive disorders should thus also be investigated in other areas of sub-
Saharan Africa, Asia and Latin America. 
 
2. Multiple pathogens can be detected in stool samples from patients and controls, which 
renders estimates of the contribution of a single pathogen to the development of intestinal 
disorders difficult. Future studies trying to explore the aetiology of infectious diseases 
should therefore employ a case-control approach. 
 
3. Future research should address new concepts pertaining to the complex aetiology of 
intestinal infectious diseases. Such an approach should include the use of highly sensitive 
molecular diagnostic methods (e.g. PCR). Additionally, multiple consecutive stool 
specimens should be obtained and analysed to document the excretion patterns in relation 
to clinically apparent infections, nutritional and environmental factors. The application of 
metagenomics and an accurate description of the intestinal microbiome will be important 
adjunctive steps. 
 
4. RDTs are important tools that help to manage intestinal infectious disorders. RDTs for 
detection of Cryptosporidium spp. and G. intestinalis have varying diagnostic accuracy. 
The urine-based POC-CCA cassette test is a useful and sensitive tool to detect S. mansoni 
infections and its suitability for case detection and clinical management of individual 
patients in endemic and non-endemic settings should be further assessed. 
 
5. The epidemiology of C. difficile in sub-Saharan Africa is poorly understood. RDTs 
should be more widely employed to investigate the presence of this bacterial pathogen in 
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samples stemming from patients with diarrhoea, asymptomatic controls, animal stool 
specimens and environmental samples. RDT-positive samples can be stored for weeks at 
ambient temperature before being sent to a laboratory for further diagnostic 
characterisation. Hospital- and community-based studies will help to estimate the 
significance of C. difficile as the causative agent of intestinal infections in sub-Saharan 
Africa. 
 
6. Strongyloidiasis is an important infection and has the potential to cause life-long 
persistence if left untreated. S. stercoralis is endemic in many parts of sub-Saharan 
Africa, but the diagnostic accuracy of currently available laboratory tests is not sufficient. 
Hence, concerted efforts should be made to develop a stool-based RDT for detection of 
S. stercoralis, which could be used for both mapping studies in tropical settings and 
individual patient management. 
 
10.7 Conclusions 
Persistent diarrhoea and persistent abdominal pain constitute important public health 
problems in many resource-limited tropical settings and may be caused by multiple intestinal 
pathogens. In the frame of the international NIDIAG research consortium, the current Ph.D. 
thesis investigated persistent digestive disorders in Côte d’Ivoire. A systematic review was 
performed to assess the aetiological spectrum of pathogens causing persistent digestive 
disorders. Subsequently, a detailed study protocol and more than 30 specific SOPs were 
developed to investigate this clinical syndrome prospectively in a multi-country study. A 
case-control study was carried out in south Côte d’Ivoire to evaluate clinical features and 
infectious agents associated with persistent diarrhoea. Further emphasis was placed on the 
epidemiology, clinical importance and diagnostic techniques for three pathogens deemed of 
particular relevance, i.e. C. difficile, S. mansoni and S. stercoralis. The following main 
conclusions can be drawn from the current work. 
 
1. Persistent diarrhoea and persistent abdominal pain are of considerable public health 
relevance in Côte d’Ivoire and elsewhere in the tropics. Most affected individuals live in 
rural, remote areas with limited access to healthcare facilities. The aetiological spectrum 
is broad and includes more than 40 bacterial, parasitic (helminths and intestinal protozoa) 
and viral pathogens. The predominating pathogens differ from one setting to another. Co-
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infections are frequently detected in both symptomatic patients and healthy controls, 
especially if highly sensitive PCR techniques are employed. The clinical relevance of 
these findings remains to be elucidated and the inclusion of asymptomatic controls should 
be encouraged in future epidemiological studies. 
 
2. S. stercoralis is endemic in Côte d’Ivoire and its reported prevalence in two different 
settings varied between 10% and 20%, depending considerably on the employed 
diagnostic techniques. Standard copromicroscopic tools (e.g. Kato-Katz technique) fail to 
detect S. stercoralis, and a combination of the Baermann funnel concentration technique 
and the Koga agar plate technique yields more accurate results. A novel, stool-based real-
time PCR for S. stercoralis has been validated in the current work and is the single most 
sensitive diagnostic technique. However, PCR alone should not replace the microscopic 
techniques. There is a need for a Strongyloides-specific rapid antigen detection test that 
can be applied on stool samples. 
 
3. C. difficile can be found in human stool samples in Côte d’Ivoire. Non-toxigenic strains 
predominate in patients and asymptomatic controls and the molecular ribotype patterns 
differ considerably from those seen in other geographical areas. An RDT-based 
diagnostic two-step algorithm has been successfully validated in Côte d’Ivoire to 
facilitate the screening of C. difficile in resource-limited settings without immediate 
access to a diagnostic laboratory. Indeed, prolonged storage of RDT-positive samples 
without properly maintained cold chain only minimally affects the subsequent recovery of 
C. difficile and its toxins in stool culture. 
 
4. Intestinal schistosomiasis is an important cause of persistent abdominal pain in 
individuals from endemic settings, even in the absence of diarrhoea or blood in the stool. 
The urine-based POC-CCA cassette test is more sensitive than standard microscopic 
techniques (e.g. Kato-Katz and formalin-ether concentration technique) for the diagnosis 
of S. mansoni. In the current work, it has been shown that this RDT can also be a useful 
tool for individual patient management outside endemic areas, e.g. in European hospitals 
caring for immigrants from Africa or returning travellers. Its use in patient groups with a 
clinical or epidemiological history suggestive of schistosomiasis is strongly encouraged. 
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